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PREFACE
This dissertation provides a detailed account of our efforts to explore the
hydrophobic tunnel of autotaxin (ATX) both through computational modeling and
rational experimental design of novel small molecules. ATX was discovered in
melanoma cells in 1992 and has since been connected to a myriad of inflammatory
diseases. After crystallization of ATX, the unique hydrophobic domain became of
interest and this work explores structure-activity relationships to understand inhibition
impact of small molecules.
Chapter 1 is a review of structure-activity relationships for autotaxin inhibition.
This invited review was submitted to Current Topics in Biochemical Research. The work
in chapter 2 covers discovery and optimization of a novel scaffold for autotaxin
inhibition. This chapter has been accepted for publication in Bioorganic and Medicinal
Chemistry. For continuity, chapter 3 (continued structure-activity relationship
exploration) is also formatted following Bioorganic and Medicinal Chemistry. Chapter 4
summarizes the work accomplished and proposes relevant future studies.
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ABSTRACT
Ragle, Lauren Elizabeth, PhD. The University of Memphis. December, 2016.
Computational and Experimental Tools to Explore Autotaxin Inhibition by Novel Small
Molecules. Major Professors: Abby L. Parrill and Daniel L. Baker.
Autotaxin (ATX) is a ubiquitous ectoenzyme that hydrolyzes lysophosphatidylcholine
(LPC) to form the bioactive lipid mediator lysophosphatidic acid (LPA). LPA activates
specific G-protein coupled receptors (GPCR) to elicit downstream effects leading to
cellular motility, survival, and invasion. Through these downstream effects, autotaxin is
involved in many diseases including cancer, heart disease, chronic pain, asthma, and
other inflammatory diseases. Inhibition of autotaxin activity is therefore a therapeutically
attractive goal.
Initial ATX inhibitors included L-histidine and analogs which acted as metal
chelators. Subsequently, LPA and sphingosine-1-phosphate were identified as ATX
inhibitors, leading to extensive structure-activity relationship (SAR) studies on
phospholipid analogs. Later, computational and experimental SAR studies led to
discovery of smaller, non-lipid molecules which could avoid off-target effects through Gprotein coupled receptor interactions. In 2011, crystal structures confirmed earlier
enzyme kinetic studies that suggested multiple inhibitor binding sites by revealing a
unique allosteric hydrophobic pocket. Further exploration of this hydrophobic pocket,
both computationally and experimentally, has been undertaken to develop new ATX
inhibitors which can take advantage of hydrophobic interactions.
In order to explore the hydrophobic tunnel of ATX, a structure-based
pharmacophore model was developed. This model was used to screen a large database of
diverse compounds, discovering a new inhibitor scaffold, GRI 392104 (IC50 4 μM). This

v

scaffold was used as a lead to develop sixty-six additional compounds. In total twelve
newly synthesized inhibitors of ATX were more potent than GRI392104 and were
selective for ATX as they had no effect on other LPC-specific NPP family members or
on LPA1-5 GPCR.
Concurrent to this work, another promising inhibitor with a similar scaffold was
discovered in collaboration with Dr. Tigyi at University of Tennessee Health Science
Center, GRI 182135 (IC50 154 nM). The potency of this compound was four-fold that of
the best compound from initial optimization of the GRI 392104 scaffold, so an additional
nine molecules were studied to explore the differences in activity, resulting in a twelvefold improvement in potency from the initial structure-activity relationship of GRI
392104 and almost three-fold improvement over the initial screening of GRI 182135.
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Chapter 1
Structure-Activity Relationships of Autotaxin Inhibition
1.1 Introduction
Autotaxin (ATX, NPP2) was confirmed in 2002 by two independent research
groups, to be the protein responsible for a long studied plasma lysophospholipase-D
(lysoPLD) activity and by extension the source of serum lysophosphatidic acid.[1,2] This
realization served as a convergence point for two previously disparate fields of study.
Historically, ATX research had been divided into investigations of enzymatic function in
plasma (via lysoPLD activity) and investigations using purified enzyme (ATX), mostly
from melanoma conditioned culture media. Studies on enzymatic function of plasma
lysoPLD were initiated in the 1980s to understand the formation of bioactive lipids in
plasma and serum.[3,4] Tokumura et al. connected plasma lysoPLD activity to the
generation of lysophosphatidic acid via hydrolysis of lysophosphatidylcholine (figure
1).[4] This work showed that addition of Co2+ or Zn2+ was beneficial to plasma lysoPLD
activity.[5] When ATX was later crystallized in 2011, the importance of divalent metals
was confirmed as two Zn2+ ions were present in the active site.[6,7] Investigations into
purified ATX enzyme began in 1992 when Stracke et al. purified an autocrine motility
factor from melanoma cells. They identified this unique glycoprotein as ATX.[8] This
work also connected ATX to pertussis toxin-sensitive G proteins, which suggested
specific downstream G-protein coupled receptor (GPCR) activation. ATX was also
determined to have both pyrophosphatase and phosphodiesterase activities including
nucleotide hydrolysis through a common catalytic site.[9] Once ATX was shown to be
responsible for plasma lysoPLD activity and thereby the primary source of plasma LPA
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(figure 1), the relationship of ATX to pertussis-toxin sensitive GPCRs seen by Stracke et
al. was validated.[8] Jansen et al. elucidated the mechanism by which ATX is released
from cells by a process of proteolytic maturation.[10]
ATX is one member of a larger pyrophosphatase/phosphodiesterase family of
ectoenzymes. ATX possesses both phosphodiesterase activity using lipid substrates, as
well as pyrophosphatase activity against nucleotide substrates.[1,2,9] This dual
specificity is unique to known NPP family members as NPP1, NPP3, and NPP4
preferentially hydrolyze nucleotides.[11-13] In contrast, NPP6 and NPP7 both utilize
lipid substrates.[14] To date the natural substrate of NPP5 remains unknown. Most
biological effects from ATX activity have been shown to be mediated by action of its
major product, LPA, on specific GPCRs.[15-17]

Figure 1.1: Generation of Lysophosphatidic Acid (LPA) by ATX-catalyzed Hydrolysis
of Lysophosphatidylcholine (LPC).
During normal homeostasis, ATX plays important roles in wound healing and in
utero blood vessel development.[18-21] However, when ATX expression/activity
becomes dysregulated, cellular proliferation and migration can lead to several disease
states including cancer and other inflammatory diseases.[8,22] Several different lines of
evidence support a role for ATX in cancer. First, as previously stated, ATX was
identified as the enzyme responsible for cell motility in melanoma A2058 cells.[8]
Second, ATX was found to increase cellular invasion through autocrine signaling
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pathways in both glioblastoma multiforme and acute myeloid leukemia.[23-25] Third,
ATX expression was shown to be connected with increased levels of inflammatory
cytokines in both breast and thyroid cancer.[17,26,27] Fourth, ATX expression is
elevated in endothelial cells lining tumor vessels of renal cell carcinoma.[28]
The role of LPA and ATX has been studied in chemotherapeutic resistance, as
well. ATX leads to acquired resistance to a common chemotherapeutic, sunitinib, which
is antagonized by treatment with an LPA1 receptor antagonist.[28] ATX-produced LPA
has also been linked to chemotherapeutic resistance in ovarian cancer cells treated with
carboplatin[29] and breast cancer cells treated with Taxol[30]. Inhibition of ATX has
been shown to sensitize cells to chemotherapy-induced apoptosis, which delays or avoids
resistance pathways.[29] Therefore, ATX inhibition is a therapeutic target for
chemotherapeutic resistance.
ATX has also been linked with other human health issues, including both liver
fibrosis and pulmonary idiopathic fibrosis.[31,32] Additionally, ATX has been
connected to coronary disease due to a marked increase in plasma LPA.[33] ATXcatalyzed production of LPA has also been implicated in models of chronic neuropathic
pain and allergic asthma.[34-36] Increased ATX expression has also been found in the
frontal cortex of Alzheimer-type dementia patients and is theorized to be a potential risk
factor marker and biological target for advanced Alzheimer’s disease.[37] ATX secreted
by adipose tissue produces LPA, resulting in negative feedback which has been linked to
obesity and obesity-related dysregulation of glucose homeostasis.[38] ATX inhibition is
thus also a therapeutic target for inflammatory diseases.
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1.2 Assays to Determine Autotaxin Activity / Inhibition
Upon hydrolysis by ATX, LPC releases both choline and LPA (figure 1.1); both
of which can be detected in medium and high throughput biochemical assays. These
assays are commonly used to determine ATX activity and to screen candidate inhibitors.
These assays make use of either natural or unnatural substrates. Natural substrates, such
as LPC, including those with varying acyl chain lengths and degrees of unsaturation have
been incorporated into several methods.[2,39-41] Radiolabeled 14C-LPC is also a direct
method, but it is not suitable for high-throughput screening due to the necessity of
purifying the product (LPA) from the starting material (LPC) before activity can be
determined.[2,42] Choline release can be detected by enzyme-catalyzed oxidation of
choline to betaine by choline oxidase, releasing hydrogen peroxide, which can react with
a variety of reagents including horseradish peroxidase to generate a detectable product,
but due to addition of other enzymes, there is a high likelihood of assay interference.[4348] LPA can be detected directly and in a highly-sensitive manner with LC-MS/MS
methods.[6,49] Several unnatural substrates have also been used to measure ATX
inhibition (table 1). These substrates are used in either absorbance or FRET-based
fluorescence assays. Both bis-4-nitrophenylphosphate and thymidine 5’-4-nitrophenyl
phosphate (pNP-TMP) release 4-nitrophenolate, which absorbs at 405 nm and can be
readily detected in a high throughput manner.[1,42,50] Another fluorescence-based
probe, TG-mTMP, was designed by Kawaguchi et al. to improve fluorescence quantum
yield and take advantage of nucleotide recognition by ATX (table 1.1).[51] Competitive
ATX inhibitors may be allosteric inhibitors or non-inhibitors of smaller substrates such as
these. Longer, FRET-based substrates such as CPF4 and FS-3 (table 1.1) can be used in
4

high throughput assays whereupon hydrolysis of the phosphodiester bond by ATX will
release a fluorescent product.[52,53]
These longer substrates may be more suitable for determining inhibition by
molecules that bind outside of the active site, in addition to those that are within the
active site. Because of the differences in binding mechanisms, more than one substrate is
typically used to identify new ATX inhibitors. For instance, hydrolysis of smaller
substrates may not necessarily be inhibited by the presence of compounds binding outside
of the central region of the active site. Therefore, a combination of both longer and
smaller substrates should be used to identify new ATX inhibitors.

Table 1.1: Unnatural Substrates Used to Study ATX Inhibition. The boxed
portion of each substrate is detected upon hydrolysis of the phosphodiester bond by
ATX.
Substrate

Detection
Absorbance at 405 nm

bis-4-nitrophenylphosphate

Absorbance at 405 nm
thymidine 5’-4-nitrophenyl phosphate (pNP-TMP)
Fluorescence system,
excitation at 490 nm
and emission at 510 nm
Arrow indicates
position of initial ATX
cleavage before release
of fluorophore.

TG-mTMP
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Table 1.1 (Continued): Unnatural Substrates Used to Study ATX Inhibition.
The boxed portion of each substrate is detected upon hydrolysis of the
phosphodiester bond by ATX.
Substrate

Detection
FRET-based
system, excitation
at 370 nm and
emission at 515 nm

CPF4

FRET-based
system, excitation
at 485 nm and
emission at 520 nm
FS-3
Because more than one assay method is typically used to asses ATX activity,
comparing ATX inhibitors is challenging. Differences in assays (substrate identity, and
enzyme and substrate concentrations) means comparisons of IC50 values (often the only
reported data) are difficult to interpret. A movement toward reporting Ki values with
experimentally determined mechanism of inhibition should be a goal of the field going
forward. In this review, reported IC50 or Ki values, where available, will be used to
compare reported ATX inhibitors using a relatively coarse scale (where good is < 100
nM, modest is < 10 µM, and poor is more than 10 µM). In addition we have analyzed all
ATX inhibitors discussed with respect to Lipinski’s ‘rule of five’ to help predict their
likely drug-like potential. Lipinski’s ‘rule of five’ can help predict whether or not new
molecules are likely to be orally bioavailable and thus ‘drug-like’.[54] Since many ATX
inhibitor publications describe a goal to create molecules which could potentially be used
6

in a clinical setting, it is important to consider whether or not new inhibitors fit the ‘rule
of five’. Compounds matching these rules should have a molecular weight less than 500,
not more than 5 H-bond donors, not more than 10 H-bond acceptors, and a calculated
Log P (CLogP) less than 5. Inhibitors matching the benchmarks of Lipinski’s rules have
a greater chance of solubility and permeability characteristics that make them candidates
for oral drug delivery. Veber et al. added additional constraints, including a limit of not
more than 10 rotatable bonds.[55] Having fewer rotatable bonds reduces the likelihood
that the compounds can adopt multiple low-energy conformations and thus have more
than one biological target. In the ideal world, potent inhibitors would have one biological
target to reduce off-target effects. Both Lipinski’s rules and Veber’s addendum were
calculated herein on molecules in ionization states expected at neutral pH using the
Molecular Operating Environment (MOE, Chemical Computing Group, Montreal,
Canada) for inclusion in all tables that follow.
1.3 Metal Chelators as Early Autotaxin Inhibitors
Tokumura et al. showed the effect of metal chelators on the activity of an
unknown serum metalloenzyme with lysophospholipase-D activity.[5] This work
identified the importance of zinc on the activity of this metalloenzyme – which was later
identified as ATX.[1,2] Indeed, when mouse and rat ATX were first crystallized in 2011,
two zinc atoms were present in the nuclease-like domain (figure 1.2).[6,7] Clair et al.
was the first to investigate compounds that act as metal chelators to understand the effect
of sequestering metal from the active site of ATX.[43] Phenanthroline, histidine, and
ethylenediaminetetraacetic acid (EDTA) were tested for ATX inhibition and all three had
some effect (table 1.2). Both LPC and pNP-TMP were used as substrates to assess ATX
7

inhibition. Although these compounds exhibited no violation to the expanded Lipinski
rules (table 1.2), potency was poor. In what would become the first structure-activity
relationship (SAR) for ATX inhibitors, it was shown that either enantiomer of histidine
was the most potent of the compounds tested with the histidine methyl ester being a close
second. Imidazole was not an inhibitor of ATX, suggesting that metal chelation alone
was not sufficient for inhibition.

Table 1.2: Select Metal Chelators with ATX Inhibition. Compound descriptors
calculated with MOE include molecular weight (g/mol), number of H-bond donors,
number of H-bond acceptors, octanol-water partition coefficient (LogP), and number of
rotatable bonds. Potency is described in qualitative terms based on IC50 or Ki values
reported where good is less than 100 nM, modest is less than 10 µM, and poor is
greater than 10 µM.
Inhibitor

Weight

Lipinski’s Rules
H-don. H-acc.

LogP

# Rot.
Bonds

Potency

180.21

0

2

2.50

0

Poor

155.16

4

3

-1.31

3

Poor

170.19

4

3

-1.16

4

Poor

Phenanthroline[43]

Histidine[43]

Histidine Methyl
Ester[43]
1.4 Exploration of Lipid-Based Inhibitors
Shortly thereafter, LPA was discovered to be a feedback inhibitor of ATX.[42,56]
In addition, ATX was also shown to hydrolyze sphingosylphosphorylcholine to generate
sphingosine-1-phosphate (S1P), which also acted as a feedback inhibitor of ATX.[42,57]
It should be noted that Benesch et al. later described this inhibition as an artifact of assay
conditions, not relevant in presence of physiological amounts of natural substrate
8

(LPC).[56] Benesch et al. showed LPA and S1P failed to inhibit ATX in the presence of
200 µM LPC, instead of the sub-physiological 1 µM concentration used in the original
report. Extensive SAR studies have since been undertaken to explore the SAR and
improve the potency of lipid-based ATX inhibitors. Notable compounds to come from
these studies are shown in table 1.3.
Investigations into LPA analogs originally investigated for their activity at the
LPA GPCR[58-60], linked ATX inhibition to both cyclic analogs of LPA (such as 2ccPA
16:1, discovered with the FS-3 assay)[61] and non-cyclic lipids (such as BrP-LPA and
VPC8a202, using the FS-3 and choline release assays, respectively).[46,62-65] Studies
of S1P analogs using FS-3 and pNP-TMP as substrates determined FTY720-P was also
an ATX inhibitor, in addition to being the bioactive form of FTY720 (an antagonist of
S1P1 signaling used for treatment of relapsing multiple sclerosis under the trade names
GILENYA® and fingolimod).[66] Additional lipids were screened as well, which lead to
the identification of a potent lipid inhibitor, S32826 (via radiolabeled LPC and choline
release assays).[67] However, S32826 was ineffective in vivo – potentially due to
hydrolysis of the linking amide bond. Gupte et al. developed Gupte 22 and Gupte 30b
assayed using FS-3 and pNP-TMP assays (table 1.3).[68] These compounds were
predicted to be more effective in vivo and solve the potential hydrolytic liability of
S32826. Indeed, both Gupte 22 and Gupte 30b showed excellent in vivo stability and
reduced lung metastases in a syngeneic mouse melanoma model.
During ATX crystallography, Keune et al. identified a region of electron density
in the hydrophobic tunnel, which lead to the discovery of bound 7-α-hydroxycholesterol
(table 1.3, figure 1.3).[47] An SAR utilizing commercially available bile salts revealed
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tauroursodeoxycholic acid (TUDCA, table 1.3), and related bile salts as ATX inhibitors.
TUDCA was shown to be a noncompetitive inhibitor using choline release studies, but
was a competitive inhibitor when using FS-3 as the substrate. This activity was further
explained by crystallographic evidence of TUDCA blocking the open hydrophobic
tunnel, which may inhibit LPA release. It is of note that most of these lipid-based
inhibitors have modest potency and their flexibility, as reflected by greater than 10
rotatable bonds for all compounds in table 1.3 other than the steroid derivatives, may
predict potential off-target effects.

Table 1.3: Select Lipid-Based Autotaxin Inhibitors. Compound descriptors
calculated with MOE include molecular weight (g/mol), number of H-bond donors,
number of H-bond acceptors, octanol-water partition coefficient (LogP), and number
of rotatable bonds. Potency is described in qualitative terms based on IC50 or Ki
values reported where good is less than 100 nM, modest is less than 10 µM, and poor
is greater than 10 µM.
Inhibitor

Lipinski’s Rules
Weight H-don. H-acc.
434.51

1

387.48

0

LogP

# Rot.
Bonds

Potency

7

4.09

21

Good

5

4.06

16

Modest

LPA 18:1[42]

2ccPA 16:1[61]
501.40

1

7

5.55

21

Good
to
Modest

646.81

2

9

6.38

25

Modest

BrP-LPA[62]

VPC8a202[65]

10

Table 1.3 (Continued): Select Lipid-Based Autotaxin Inhibitors. Compound
descriptors calculated with MOE include molecular weight (g/mol), number of H-bond
donors, number of H-bond acceptors, octanol-water partition coefficient (LogP), and
number of rotatable bonds. Potency is described in qualitative terms based on IC50 or
Ki values reported where good is less than 100 nM, modest is less than 10 µM, and
poor is greater than 10 µM.
Lipinski’s Rules
Inhibitor

#
Rot.
Bond
s

Potency

Weight

H-don.

H-acc.

LogP

378.47

4

5

2.93

17

Good

386.45

4

5

2.93

14

Modest

395.48

1

4

4.88

16

Good

380.51

0

3

6.77

16

Modest

400.50

0

3

6.95

13

Modest

402.66

2

2

6.61

5

Not
Reported

498.71

3

6

3.35

8

Modest

S1P[42]

FTY720-P[66]

S32826[67]

Gupte 22[68]

Gupte 30b[68]

7-αhydroxycholesterol[47]

TUDCA[47]
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1.5 Small-Molecule, Drug-Like Inhibitors
Until 2008, the most potent ATX inhibitors were lipids. In that year, H2L
7905958 was reported as the first small molecule, drug-like inhibitor of ATX (table
1.4).[69] Although it has one violation of the Lipinski rules, with a molecular weight
slightly above 500 g/mol, H2L 7905958 was the first non-lipid inhibitor of ATX with
potency in the low micromolar range, as determined by FS-3, pNP-TMP, and choline
release assays.[70] Optimization of this compound showed potency could be improved
by installing a trifluoromethyl group into the meta position of the phenylthiourea ring
(Hoeglund 11) instead of the initial 3,5-dichloro substitution pattern, although this turned
the competitive inhibitor into a non-competitive inhibitor which selectively bound to
ATX without effect on catalytic function of NPP6 and NPP7 (lysophospholipid-binding
relatives of ATX).[71]
Other groups[39,72-76], such as Saunders et al.[77], also began exploring small
molecule inhibitors to improve on potency, bioavailability, and specificity. During a
diversity screen of small molecules, Sanders et al. observed inhibition of ATX using both
pNP-TMP and FS-3 as substrates. This resulted in the discovery of molecules such as
biothionol and NSC 48300 (table 1.4). Biothionol showed poor potency and one
violation to the expanded Lipinski rules. NSC 48300, on the other hand, was more potent
and showed no Lipinski violations. Inhibition of ATX by these compounds proved to
reduce motility and migration of melanoma cells.
During a high throughput screen, Albers et al. identified HA 51 with a
combination of substrates including CPF4, bis-pNPP, and LPC. Later, this
thiazolidinedione was optimized to HA 155 (potency determined by choline release
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assay, table 1.4) by changing the carboxylic acid into a boronic acid which could
covalently bind to the nucleophilic threonine in the active site of ATX, although this
binding was shown to be reversible.[50,78] Another group working with boronic acid
compounds were able to obtain a potent, non-covalent inhibitor of ATX using a novel
substrate of their own design, TG-mTMP. However, they did not compare inhibition of
ATX by their compounds, such as 3BoA (table 1.4), by using other substrates that are
used more pervasively in literature.
Inspired by patented compounds, such as Merck B50 (potency determined by
choline release) [79], Pfizer developed PF-8380 – one of the most potent ATX inhibitors
to date – using FS-3 and LPC with tandem mass spectroscopy[49] (table 1.4). PF-8380
was shown to reduce LPA levels during inflammation. This small molecule is orally
bioavailable, as it proved effective against arthritis upon oral dosing in rats. PF-8380 can
be used as a tool to further understand the connection between ATX and inflammatory
diseases. Merck has gone on to generate other inhibitors with a scaffold similar to both
Merck B50 and PF-8380, such as Merck 19[80] and Merck 17[81] (table 1.4). Other
groups have also synthesized compounds with a polar moiety (such as triazole) and short,
hydrophobic tails, as shown in Novartis 35[82] and Eli Lilly example 1[83] (table 1.4).
Merck 17, Novartis 35, and Eli Lilly example 1 all had potency determinations using
choline release assays. While the scaffolds were changed slightly in the expanded SAR
studies, a recurring theme was dichloro substitution on an aromatic ring. Indeed, this had
already been seen with other compounds, such as H2L 7905958.
The availability of crystal structures can allow for structure-based discovery of
new scaffolds. Indeed, Fells et al. has made use of such structures to understand how
13

small-molecule inhibitors were binding and realized the unique hydrophobic pocket of
ATX makes for an allosteric binding site for inhibition by compounds such as 918013
and 403070 (table 1.4) as well as others in that SAR series.[84,85] Potencies for these
compounds were determined by a combination of FS-3, pNP-TMP, and choline release
assays. Crystallographic techniques have also been applied to ATX complexes with
small-molecule inhibitors in order to inform SAR decisions, leading to compounds such
as PAT-494, PAT-352, PAT-078, and PAT-347 (table 1.4).[75] Potency for these
compounds was determined in a combination of assays including FS-3, bis-NPP, and
choline release. Although not available in the Protein Data Bank, Galapagos has shown a
crystal structure of GLPG-1690 in presentations, indicating this potent drug compound
(as determined by both FS-3 and choline release assays) has been crystallized in ATX,
showing occupancy in both the hydrophobic pocket and hydrophobic tunnel.[76] GLPG1690 was optimized from previous inhibitors, such as compound 171 (table 1.4).[86] It is
of note that GPG-1690 is also the only ATX inhibitor currently entering phase II clinical
trials.[76,86]

Table 1.4: Select Small-Molecule Autotaxin Inhibitors. Compound descriptors
calculated with MOE include molecular weight (g/mol), number of H-bond donors,
number of H-bond acceptors, octanol-water partition coefficient (LogP), and number
of rotatable bonds. Potency is described in qualitative terms based on IC50 or Ki
values reported where good is less than 100 nM, modest is less than 10 µM, and poor
is greater than 10 µM.
Inhibitor

Lipinski’s Rules
Weight H-don. H-acc. LogP

506.37

1

H2L 7905958[69]
14

5

2.12

# Rot.
Bonds

Potency

6

Modest

Table 1.4 (Continued): Select Small-Molecule Autotaxin Inhibitors. Compound
descriptors calculated with MOE include molecular weight (g/mol), number of Hbond donors, number of H-bond acceptors, octanol-water partition coefficient (LogP),
and number of rotatable bonds. Potency is described in qualitative terms based on
IC50 or Ki values reported where good is less than 100 nM, modest is less than 10 µM,
and poor is greater than 10 µM.
Inhibitor

Lipinski’s Rules
Weight H-don. H-acc. LogP

# Rot.
Bonds

Potency

505.50

1

5

1.80

7

Modest

356.06

2

2

6.04

2

Poor

412.06

0

6

4.18

4

Modest

474.51

0

6

5.78

8

Modest

463.29

2

5

5.41

7

Good

477.20

2

4

5.00

5

Good

496.42

2

5

2.92

9

Not
Reported

Hoeglund 11[71]

Bithionol[77]

NSC 48300[77]

HA 51[45]

HA 155[48]

3BoA[51]

Merck B50[79]
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Table 1.4 (Continued): Select Small-Molecule Autotaxin Inhibitors. Compound
descriptors calculated with MOE include molecular weight (g/mol), number of Hbond donors, number of H-bond acceptors, octanol-water partition coefficient (LogP),
and number of rotatable bonds. Potency is described in qualitative terms based on
IC50 or Ki values reported where good is less than 100 nM, modest is less than 10 µM,
and poor is greater than 10 µM.
Inhibitor

Lipinski’s Rules
Weight H-don. H-acc. LogP

# Rot.
Bonds

Potency

479.34

2

5

3.36

8

Good

518.43

2

5

4.02

7

Modest

405.34

2

4

5.18

8

Modest

440.33

1

5

3.38

9

Modest

441.50

2

6

0.57

6

Good

433.29

1

4

2.62

5

Good

492.22

1

3

4.63

5

Good

PF-8380[49]

Merck 19[80]

Merck 17[81]

Novartis 35[82]

Eli Lilly Example 1[83]

918013[84]

403070[85]
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Table 1.4 (Continued): Select Small-Molecule Autotaxin Inhibitors. Compound
descriptors calculated with MOE include molecular weight (g/mol), number of Hbond donors, number of H-bond acceptors, octanol-water partition coefficient (LogP),
and number of rotatable bonds. Potency is described in qualitative terms based on
IC50 or Ki values reported where good is less than 100 nM, modest is less than 10 µM,
and poor is greater than 10 µM.
Inhibitor

Lipinski’s Rules
Weight H-don. H-acc. LogP

# Rot.
Bonds

Potency

349.37

1

2

3.36

2

Good

349.37

1

2

3.36

2

Good

420.42

0

4

3.27

5

Good

395.41

0

3

6.41

6

Good to
Modest

505.93

0

3

6.68

5

Good

546.70

1

4

3.95

9

Good

588.71

2

5

2.16

9

Good

PAT-494[75]

PAT-494[75]

PAT-352[75]

PAT-078[75]

PAT-347[75]

Galapagos Compound
171[86]

GLPG-1690[86]
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1.6 Irreversible Autotaxin Inhibitors
While the field continues to explore reversible small-molecule inhibitors of ATX,
other types of inhibitors have also been characterized. Irreversible inhibitors can be
useful as a means to understand the active conformation of the enzyme in addition to
being potential treatments for ATX-related diseases. While potency was not reported for
Example 3 (table 1.5), activity was measured by decreasing hydrolysis of FS-3.[87] This
compound acts as a mechanism-based irreversible inhibitor of ATX, whereupon
hydrolysis of the phosphodiester bond produces a reactive quinone methide that can bind
to a nucleophile in the active site. Vinyl sulfone compounds, such as CVS-16, are also
irreversible inhibitors of ATX activity.[88] These compounds were also analyzed with
an FS-3 assay, but dilution assays were also performed to see if the binding was
reversible. In fact, the binding of CVS-16 to ATX was irreversible. While CVS-16
showed reduction in tumor volume and serum ATX in melanoma mouse models, PF8380 did not have a significant impact on melanoma tumor progression when analyzed
via the same method. When CVS-16 was given at high dosages for an extended period of
time, however, dehydration was evident in the mice and diets were supplemented to
combat this side effect. Due to the violations to expanded Lipinski rules, these
irreversible inhibitors may not be readily bioavailable and further exploration of this is
needed should these types of inhibitors be further developed for clinical use.
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Table 1.5: Mechanism-Based Autotaxin Inhibitors. Compound descriptors
calculated with MOE include molecular weight (g/mol), number of H-bond donors,
number of H-bond acceptors, octanol-water partition coefficient (LogP), and number
of rotatable bonds. Potency is described in relative terms of known IC50 or Ki values
in various assays where good is less than 100 nM, modest is less than 10 µM, and
poor is greater than 10 µM.
Lipinski’s Rules

Inhibitor

H-acc. LogP

# Rot.
Bonds

Potency

Weight

H-don.

447.52

0

2

8.04

19

Not
Reported

416.74

0

2

7.02

20

Modest

University of Memphis
Example 3[87]

CVS-16[88]
1.7 Structural Insights into Autotaxin Inhibitor Binding Sites
Autotaxin has been crystallized from three different species: mouse (figure 1.2),
rat, and human.[6,7,47,51,75,78] All three show common structural features including a
nuclease-like domain, somatomedin-B-like domains, and a central catalytic domain.
Within the catalytic domain, there is an open polar active site, a hydrophobic tunnel, and
a hydrophobic pocket. The crystal structures confirmed the presence of zinc and calcium,
as theorized by both Tokumura et al. and Clair et al. during their work with metal
chelators as ATX inhibitors.[5,43] The calcium ion is in the nuclease-like-domain, not
the catalytic domain. This could explain why the presence of calcium enhanced ATX
activity but could not overcome inhibition caused by histidine.[43]
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Figure 1.2: A Representative ATX Crystal Structure (PDB ID: 3NKM). The two Nterminal somatomedin-B-like domains are shown as a blue ribbon. The catalytic
domain is shown as a pink ribbon with the surface around the binding site rendered
with hydrophobic surfaces in green and hydrophilic surfaces in blue. Two zinc ions
(aqua spheres) are in the active site. A calcium ion (brown sphere) is in the nucleaselike-domain (red ribbon). Two linker regions are shown as a dark gray ribbon.
Several crystal structures of ATX in complex with ligands have been published in
recent years. Since mouse, rat, and human ATX have high sequence homology (over
95%), the bound structures were aligned to compare inhibitor binding across multiple
studies. Figure 3 shows the positions of various co-crystallized compounds
superimposed into the catalytic domain of mouse ATX (PDB ID: 3NKM), which were
downloaded from the Protein Data Bank.[7,89] The empty mouse ATX structure is
combined with a schematic to more easily visualize the active site, hydrophobic tunnel,
and hydrophobic pocket where inhibitors can bind (figure 1.3, panel A). One of the first
crystal structure papers discussed a series of LPA-bound structures with differing chain
lengths (figure 1.3, panel B).[7] The polar head group is shown in complex with the
active site and the tail terminates in the hydrophobic pocket. It was theorized that the
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hydrophobic tunnel was an open exit tunnel for the product. While this may be true,
inhibitors that block the tunnel, such as the bile salts discovered by Keune et al., are noncompetitive inhibitors of LPC hydrolysis, although they do show competitive inhibition
for FS-3 hydrolysis (figure 1.3, panel C).[47]
Small molecules have also been crystallized in complex with ATX by multiple
groups. The reversible covalent binding of HA155 to the catalytic threonine was
explained by Hausmann et al. using one of the first ATX complexes with a small
molecule inhibitor.[6] The crystal structure of HA155 contained a tetrahedral boron,
which is indicative of forming a covalent bond with the catalytic threonine. Albers et al.
showed this covalent bond was reversible by utilizing a washout assay.[45] Kawaguchi
et al. published ATX complexes with other boronic acid inhibitors, like 3BoA, in which
boron has a trigonal planar geometry, indicating a noncovalent interaction with the polar
active site.[51] Modeling-based discovery of novel inhibitors of ATX may need to
include water in the simulations because, as mentioned by Kawaguchi et al., ATX may
interact with some inhibitors via a bridging water molecule. Both boronic acid analogs
were shown to interact with the polar active site and terminate in the hydrophobic pocket
(figure 3, panel D). In the first crystal structure of human ATX, Stein et al. provide
further evidence supporting the importance of evaluating inhibitors using multiple
substrates as analogous compounds can bind in different areas of the catalytic
domain.[75] They coupled the crystallographic data with mechanistic determinations for
each compound. PAT-352, which is analogous to PAT-494 (table 1.4), is shown in two
locations within the catalytic domain – one in the hydrophobic tunnel and one in the
hydrophobic pocket (PDB ID: 4ZG9, figure 1.3, panel E). PAT-494, the smaller analog,
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is also shown in the hydrophobic pocket (PDB ID: 4ZGA, figure 1.3, panel E). Both of
these compounds are mixed mode-inhibitors of choline release from LPC, but only PAT352 shows inhibition with FS-3. The other two potent inhibitors studied by Stein et al.
are PAT-078 and the analogous compound, PAT-347 (table 1.4). As seen in the crystal
structures (figure 1.3, panel F), PAT-078 is in the hydrophobic pocket of ATX while
PAT-347 occupies the hydrophobic tunnel. These binding differences can explain why
PAT-078 is a competitive inhibitor, showing residency in the hydrophobic pocket which
would typically be occupied by the lipophilic tail of the natural substrate, LPC.
Meanwhile, PAT-347 is a non-competitive inhibitor, much like the bile salts, occupying
the hydrophobic tunnel. Even though compounds are analogous to one another, the
binding position differences displayed in these crystal structures demonstrate that they
may not occupy the same binding site the ATX catalytic domain. As more small
molecules are developed for ATX inhibition, crystal structures such as these can be used
as a tool to understand binding and how it relates to inhibitory activity of novel
compounds.
Although computational modeling identified the first non-lipid inhibitors of ATX
using a model that only included the catalytic domain[69], the crystallographic ATX
structures provide more complete starting points for structure-based discovery of novel
inhibitors. This has been done by multiple groups, including Fells et al. in the discovery
of small molecule inhibitors of ATX and optimization of those inhibitors to obtain
918013 and 403070, as well as other compounds (table 4).[84,85] Modeling and
crystallographic evidence both point to the hydrophobic pocket as an important area for
ATX inhibition, as seen in figure 1.3, panels D, E, and F. Further development of
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computational models that use existing crystallographic data will discover new inhibitors
in the future.

Figure 1.3: Crystallographic Positions of Known ATX Inhibitors as Superposed in
mATX (PDB ID: 3NKM). Panel A shows the empty active site of mATX with a
cartoon indicating the locations of the polar active site, the hydrophobic tunnel, and
the hydrophobic pocket.[7,89] Panel B shows the structures of crystallized LPA
extending from the active site down into the hydrophobic pocket (PDB ID: 3NKN,
3NKO, 3NKP, 3NKQ, and 3NKR).[7,89] Panel C displays both 7-αhydroxycholesterol (fuchsia, table 2, PDB ID: 5DLT) and TUDCA (black, table 1.2,
PDB ID: 5DLV).[47,89] Panel D shows the locations of 3BoA (black, table 1.3,
PDB ID: 3WAX, [51]) and HA 155 (fuchsia, table 1.3, PDB ID: 2XRG, [6]).[89]
Panel E shows two possible binding locations of PAT-352 (fuchsia, table 1.3, PDB
ID: 4ZG9) and one crystallized location of PAT-494 (black, table 1.3, PDB ID:
4ZGA).[75,89] Panel F displays different binding locales of inhibitor analogs PAT078 (black, table 1.3, PDB ID: 4ZG6) and PAT-347 (fuchsia, table 1.3, PDB ID:
4ZG7).[75,89]
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1.8 Concluding Remarks
The connection of ATX to various disease states has led to an increased interest in
studying inhibition. These studies have informed the field in how molecules interact with
ATX, leading to compounds that can potentially be used as leads toward treatment
strategies for ATX-related diseases. The most potent inhibitors to date have an overall
amphipathic quality with a polar group and relatively non-polar, aromatic substituents.
S32826, the most potent lipid-based inhibitor, contains a phosphonate head group
connected to an N-phenylactylamide (table 1.3). PF-8380, the most potent small
molecule inhibitor, has a substituted benzo[d]oxazol-2(3H)-one head group and a 3,5dichlorobenzyl moiety (table 1.4). However, PAT-352, PAT-078, and PAT-347 have a
carboxylate with various aromatic substituents (table 1.4). Reduction of flexibility by
making use of ring systems instead of long, lipid tails has also lead to compounds with
increased specificity, which can translate into fewer side effects when used as
pharmaceutical agents. For instance, LPA and S1P (table 1.3) act as ATX inhibitors and
agonists for GPCR signaling,[15-17,42,57] whereas Hoeglund 11 (table 1.4) has
markedly fewer rotatable bonds and has been shown to be selective for ATX over lipidbinding family members NPP6 and NPP7.[71] Additionally, GLPG-1690 was developed
with reduced flexibility and basicity, making use of crystal structures and activity
assays.[76] Optimizing the piperazine ring on GLPG-1690 allowed for reduced
inhibition of hERG, which is associated with sudden death. With the plethora of
crystallographic data available, the field will continue to expand the discovery and
optimization of new inhibitors by using existing crystal structures for structure-based
modeling or by solving structures of inhibitors in complex with ATX. Continued
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structure-activity relationship studies will explore new scaffolds to find differing
mechanisms of binding to ATX which can be useful to further understand the activity of
this ubiquitous enzyme. There is a relatively high attrition rate when converting hit
compounds into approved drugs, as described by both Hughes et al. and Bochardt.[90,91]
In Alzheimer’s disease, for instance, the attrition rate for compounds moving through
clinical trials increased with each phase.[92] Over a decade, only 0.4% of Alzheimer’s
drugs entering clinical trials gained regulatory approval after Phase 3. Failure rates may
vary substantially in different diseases, but having more than just a relatively small
number of potent, drug-like compounds will increase the chances of future conversion of
ATX inhibitors into clinically-useful drugs.
Currently, GLPG-1690 is the only ATX inhibitor in clinical trials (table 1.4, for
idiopathic pulmonary fibrosis). However, there are several other scaffolds available with
nanomolar potencies. These scaffolds could be investigated in cytotoxicity assays and
mouse models to analyze pharmacokinetics and pharmacodynamics before moving into
the clinical setting as potential treatments for other ATX-related diseases. An analog of
S32826 was injected into ATX-heterozygous mice to treat allergic asthma, reducing
plasma LPA levels and decreasing lung inflammation.[35] This demonstrates ATX could
be a viable target for the treatment of severe asthma. ATX inhibitors could also be
examined in coronary artery syndrome, where it has been shown that patients have
significantly higher concentrations of ATX.[33] Inhibition of ATX activity could also be
a potential treatment for Alzheimer-type dementia.[37] The field has been focused on
cancer research, as ATX was initially identified from melanoma cells. However, the field
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would benefit from analyzing potent inhibitors in systems to target other ATX-related
diseases as well.
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Chapter 2
Discovery and Synthetic Optimization of a Novel Scaffold for Hydrophobic TunnelTargeted Autotaxin Inhibition
2.1 Introduction
Autotaxin (ATX, NPP2, lysoPLD) is a ubiquitous, secreted enzyme in the
nucleotide pyrophosphatase/phosphodiesterase (NPP) family.[1,2,10,14] NPP1-4 are
capable of hydrolyzing phosphoanhydrides whereas NPP 2, 6, and 7 hydrolyze
phosphodiester linkages.[12-14] To date the natural substrate for NPP5 remains
unknown. Within this family only ATX is capable of cleaving both phosphoanhydride
and phosphate ester bonds, although it exhibits preference for phosphate esters.[1,2,9,57]
Regiochemically, ATX has lysophospholipase-D (lysoPLD) activity, allowing it to
hydrolyze lysophosphatidylcholine (LPC) to generate the bioactive lipid,
lysophosphatidic acid (LPA) and choline (figure 2.1).[1,2,14] Through this lysoPLD
activity, ATX is the primary source of plasma LPA.[4] Much of the biological activity of
ATX can be attributed to LPA, which prompts several signaling cascades through the
activation of specific G-protein coupled receptors which stimulate cell proliferation,
survival and migration.[15-17] Through this downstream signaling of LPA, ATX is
necessary for embryonic development of the neural tube and also plays a role in wound
healing.[18-20] ATX also plays an essential role in blood vessel formation during
embryogenesis as knockouts are non-viable due to defects in angiogenesis.[21] However,
upregulated ATX and subsequently increased level of LPA have been linked to
oncogenic transformation, cancers metastasis and therapeutic resistance, cardiovascular
disease, Alzheimer’s disease, and neuropathic pain.[2,17,33,34,37] The relationship
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between ATX and human disease makes it a potential therapeutic target. The goal of this
project is to discover novel small-molecule non-lipid drug-like inhibitors of ATX by use
of a structure-based pharmacophore, targeting the hydrophobic tunnel of ATX.

Figure 2.1: ATX-catalyzed Hydrolysis of Lysophosphatidylcholine to Lysophosphatidic
Acid.
Pharmacophores are geometrical models of structural features important for
biological activity.[93] Pharmacophores can be either ligand-based, where ligand
commonalities alone are utilized, or structure-based, where ligand similarities are taken
into account in context of their interactions in a target protein.[94] North et al., Mize et
al., and Norman et al.utilized ligand-based techniques to develop pharmacophores for
ATX, but the present work differs because it is one of the first structure-based
pharmacophores for ATX (Fells et al. also reported a structure-based pharmacophore
targeting the hydrophobic pocket of ATX).[85,95-97] Recent crystallized structures of
ATX are useful tools from which to develop structure-based
pharmacophores.[6,7,47,51,75] Crystal structures of mouse, rat, and human ATX all are
composed of three main domains, including a catalytic domain, which contains a polar
active site, a hydrophobic tunnel, and a hydrophobic pocket (figure 2.2). The prevalence
of non-polar amino acid sidechains in the hydrophobic tunnel of ATX might lead to a
structure-based pharmacophore that contains predominantly non-specific hydrophobic
features, capable of finding compounds which fit into the ATX hydrophobic pocket but
may also bind to other receptors. Aromatic features can provide essential interaction
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directionality that can potentially improve specificity as aromatic rings show strong
preference to interact in either an edge-to-face or face-to-face orientation.[98] Aromatic
features were deliberately included in the pharmacophore utilized here in high-throughput
virtual screening of large databases to discover a variety of new and hopefully selective
scaffolds for potential inhibitors which may be worthwhile to pursue further with
structure-activity relationship studies.

polar active site
hydrophobic tunnel
hydrophobic pocket

Figure 2.2: One of the Recently Published ATX Mouse Crystal Structures (PDB
ID: 3NKM).[7,89] The two N-terminal somatomedin-B-like domains are in
blue. The catalytic domain is pink and shows the surface around the binding
sites; hydrophobic surfaces are green and polar surfaces are purple. The two
zinc ions in the active site are shown in teal. The nuclease-like domain is dark
red. The two linker regions are dark gray.
In this chapter, we describe the formation of a structure-based pharmacophore
which lead to the discovery of several hydrophobic, yet non-lipid inhibitors of ATX.
These compounds docked within the same volume occupied by the initial non-lipid
inhibitors of ATX used to build the pharmacophore. Violations to Lipinski’s Rule of Five
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were calculated for each compound to filter out compounds that are not drug-like.[54] In
order to sample the entirety of the chemical space found by the pharmacophore,
compounds were grouped together into clusters based on similarity. Representatives
from each cluster were tested for ATX inhibition using two assays, one using a FRETbased substrate, FS-3, and the other using a nucleotide substrate, p-nitrophenyl 5’thymidine monophosphate. Of the seventy-two compounds tested, four inhibited FS-3
hydrolysis of ATX by 50% or greater at a concentration of 10 µM. Sixty-six analogs of
one lead were synthesized to explore the structure-activity relationship of this novel
scaffold. Thirty-six compounds inhibited ATX-catalyzed FS-3 hydrolysis by 50% or
greater at a concentration of 10 µM, with one compound having a sub-micromolar
potency.
2.2 Experimental Methods
2.2.1 ATX Protein Model Development
To compare known ATX structures and to prepare a useful template for structurebased pharmacophore development for AXT inhibition, crystal structures of mouse (PDB
ID: 3NKM[7] and rat (PDB ID: 2XR9[6]) ATX were downloaded from the Protein Data
Bank (PDB[89]) and the FASTA sequence of human ATX (Q13822) was obtained from
the National Center for Biotechnology Information.[99] Since the human ATX sequences
show high sequence similarity to the mouse (95%) and rat (94%) homologues, the
available mouse and rat structures were carefully scrutinized using MOE (Molecular
Operating Environment, Chemical Computing Group, Montreal, Canada). The rat and
mouse tertiary structures are very similar (0.70 Å alpha carbon root-mean-square
deviation (RMSD)) as would be expected based on their similar primary sequences.
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However, the rat structure lacked several backbone atoms. Likewise, the mouse structure
contained fifteen residues truncated to alanine. These truncations were spread across
three regions: the N-terminal domain (K59, E67, and K104), the catalytic domain (R162,
R244, F274, N398, L458, and K462), and the nuclease-like domain (R549, Q559, R602,
E642, and K666). Full amino acids sidechains (appropriate for each position) were added
to the mouse structure MOE using the structure preparation tool, the corrected structure
was energy minimized and validated through aligned with crystal structure (PDB ID:
3WAV[51]).
2.2.2 Pharmacophore Creation
Two potent ATX inhibitors, KM04131[95] and PF8380[49] were previously
docked into mouse ATX.[95] A consensus pharmacophore was built where similar
annotation points from these structurally distinct ligands would become a feature point
for the model. The annotation points were predominately hydrophobic or aromatic,
leading to a pharmacophore with hydrophobic and aromatic features. An exclusion
volume shape with a radius of 4Å, was added to the pharmacophore to make use of the
structural information obtained from docking. The exclusion volume shape excludes
compounds which dock outside of the general volume of the initial lead compounds.
This pharmacophore was analyzed against an internal database of 457 compounds with
measured ATX inhibitory activity (111 actives and 346 inactives)[95] to calculate
performance metrics (equations 1-5).[100] The resulting pharmacophore was used to
search the Genomic Research Institute (GRI) database of ~340,000 searchable
compounds with unknown ATX activity from the University of Cincinnati Drug
Discovery Center (UC-DDC).
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2.2.3 In Silico Candidate Inhibitor Screening
Candidate compounds, selected using the structure- based pharmacophore, were
docked into the crystal structure of mouse ATX to observed modeled interactions. The
receptor was prepared with Autodock Tools for use as a docking target by Autodock
Vina.[101] A grid box was also prepared in Autodock Tools, to focus the docking search
into the catalytic domain of ATX. The box center had x,y,z coordinates of 21.383,
36.532, and 7.403 (within 3 Å of the backbone carbonyl oxygens of both Lys 208 and
Asp 358 as well as the sidechain amide of Asn 212 and the β carbon of His 359)
respectively, with x,y,z side lengths of 40 Å, 30 Å, and 30 Å. All GRI compounds were
docked flexibly into the rigid ATX structure using Autodock Vina.
Structures selected by the pharmacophore that docked within the exclusion
volume shape were analyzed with Lipinski’s rules to exclude those exhibiting structural
features not commonly found in orally bioavailable drugs.[54] Those with greater than 5
hydrogen-bond donors, 10 hydrogen-bond acceptors, a log partition coefficient above 5,
or a molecular weight above 500 Daltons were removed from the candidate set. The
remaining candidates were clustered into groups by similarity using the Tanimoto
coefficient[102] calculated on the basis of MACCS structural keys (MDL Information
Systems Inc., San Leandro, California). Those within 55% similarity of one another were
grouped into clusters. In order to sample a variety of chemical scaffolds, visual
inspection of the most representative scaffold in each cluster lead to selecting 72 unique
compounds for in vitro screening.
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2.2.4 Enzyme Expression and Purification
Human FLAG-fusion constructs of ATX, NPP6, and NPP7 were expressed and
purified as previously described.[96]
2.2.5 In Vitro Screening
Two ATX activity assays were used as previously described.[97] The primary
ATX activity assay used FS-3 (Echelon Biosciences, Salt Lake City, Utah[53]), a long
substrate which contains a dabcyl quencher. When hydrolyzed by ATX, the
carboxyfluorescein fluorophore, becomes detectable by fluorescence. A secondary ATX
activity assay used para-nitrophenyl thymidine-5’-monophosphate (pNP-TMP, SigmaAldrich, St. Louis, Missouri), a short substrate which releases a detectable chromophore,
para-nitrophenolate. All assays were performed in triplicate using 96-well half-area
plates (Corning, Corning, New York) and were monitored using a BioTek Synergy 2
multi-detection microplate reader (BioTek Instruments, Winooski, Vermont). Control
assays were done using 10 µM inhibitor candidate with and without 100 nM
carboxyfluorescein (Sigma-Aldrich) or 100 µM para-nitrophenol (Sigma-Aldrich), as
assay controls. A preliminary single dose assay to determine ATX inhibition consisted of
10 µM compound, 10 nM ATX in assay buffer (30 µM bovine serum albumin (BSA) in
50 mM Tris pH 8.0, 1 mM CaCl2, 1 mM MgCl2, 5 mM KCl, and 140 mM NaCl), and
either 1 µM FS-3 or 1 mM pNP-TMP. For the carboxyfluorescein control and FS-3
assays, fluorescence was recorded at excitation and emission wavelengths (485 and 520
nm, respectively) for 60 minutes at 37°C. Absorbance was recorded at 405 nm for the
same length of time and temperature for the para-nitrophenolate and pNP-TMP assays.
Readings were taken every two minutes and normalized between a negative control
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(substrate with no ATX, set to 0%) and a positive control (substrate with ATX and no
compound, set to 100%). A dose response assay was done for compounds showing
greater than 50% inhibition at 10 µM, with inhibitor concentrations ranging from 0.03
µM to 30 µM, 10 nM ATX in assay buffer, and either 1 µM FS-3 or 1 mM pNP-TMP.
For dose response results, non-linear regression analysis was done to determine the IC50
for each inhibitor (GraphPad Software Inc., La Jolla, California).
2.2.6 ATX Inhibitor Specificity: Testing NPP6/7 Inhibition
Specificity for ATX inhibition was determined by measuring NPP6/7 induced
hydrolysis of a synthetic substrate, para-nitrophenylphosphocholine (pNPPC, SigmaAldrich, St. Louis, Missouri) which releases para-nitrophenolate. Assays were performed
in triplicate using 96-well half-area plates (Corning, Corning, New York) with
absorbance monitored at 405 nm and 37 °C using a BioTek Synergy 2 multi-detection
microplate reader (BioTek Instruments, Winooski, Vermont). Final concentrations on the
plate were 10 µM ATX inhibitor, 10 nM NPP6 in assay buffer (500 mM NaCl, 100 mM
Tris-HCl, 0.05% Triton X-100, pH 9) or 10 nM NPP7 in assay buffer (50 mM Tris-HCl,
150 mM NaCl, 10 mM taurocholate, pH 8), and 10 µM pNPPC in appropriate assay
buffer. Readings were taken every two minutes for an hour and normalized between a
negative control (no enzyme, set to 0%) and a positive control (with enzyme, set to
100%). After background absorbance was subtracted for each compound, data was
reported as a mean percent response relative to the positive control.
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2.2.7 ATX Inhibitor Specificity: LPA1-5 Assays
To confirm ATX specificity of 22, calcium mobilization assays were completed
for lysophosphatidic acid receptors 1-5 (LPA1-5) as previously described using a
FlexStation plate reader (Molecular Devices, San Diego, California).[103]
2.2.8 GRI 392104 Analog Design
A structure-activity relationship examination was undertaken for the most potent
and synthetically tractable inhibitor (GRI 392104) identified from this initial screen.
Changes in the lead included shortening the flexible carbon chain (linker), changing the
position of the nitro group on the phenyl piperazine segment, and altering the halogen
substituents on the terminal ring (table 2.1).

Table 2.1: GRI 392104 analog design
Analog
1,2,3
4,5,6
7,8,9
10
11
12,13,14
15,16,17
18,19,20
21
22
23,24,25
26,27,28
29,30,31
32
33

Y1
NO2
NO2
NO2
NO2
NO2
---------------------

Y2
----------NO2
NO2
NO2
NO2
NO2
-----------

Y3
--------------------NO2
NO2
NO2
NO2
NO2

X1
Cl, F, CF3
----Cl
--Cl, F, CF3
----Cl
--Cl, F, CF3
----Cl
---
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X2
--Cl, F, CF3
----Cl
--Cl, F, CF3
----Cl
--Cl, F, CF3
----Cl

X3
----Cl, F, CF3
Cl
------Cl, F, CF3
Cl
------Cl, F, CF3
Cl
---

X4
--------Cl
--------Cl
--------Cl

Table 2.1 (Continued): GRI 392104 analog design
Analog
34,35,36
37,38,39
40,41,42
43
44
45,46,47
48,49,50
51,52,53
54
55
56,57,58
59,60,61
62,63,64
65
66

Y1
COOH
COOH
COOH
COOH
COOH
---------------------

Y2
----------COOH
COOH
COOH
COOH
COOH
-----------

Y3
--------------------COOH
COOH
COOH
COOH
COOH

X1
Cl, F, CF3
----Cl
--Cl, F, CF3
----Cl
--Cl, F, CF3
----Cl
---

X2
--Cl, F, CF3
----Cl
--Cl, F, CF3
----Cl
--Cl, F, CF3
----Cl

X3
----Cl, F, CF3
Cl
------Cl, F, CF3
Cl
------Cl, F, CF3
Cl
---

X4
--------Cl
--------Cl
--------Cl

Figure 2.3: Synthetic Scheme to Make Analogs of GRI 392104 with R=NO2 or
COOH and X=F, Cl (mono), Cl (di), or CF3. Activation of the carboxylic acid
requires O-(Benzotriazol-1-yl)-N,N,N’,N,’-tetramethyluronium
hexafluorophosphate (HBTU) with diisopropylethylamine (DIPEA).

2.2.8.1 General Procedure for Nitro Analog Synthesis
Thirty-three nitro-containing analogs of GRI392104 (table 2.1) were synthesized
using a two-step reaction (figure 2.3). To a dry round bottom flask, 190 µmol of
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carboxylic acid building block, 190 µmol of HBTU (O-(benzotriazol-1-yl)-N, N, N’,N’tetramethyluronium hexafluorophosphate) and 190 µmol of N,N-diisopropylethylamine
(DIPEA) were combined in 1 mL of N,N-dimethylformamide (DMF) and stirred for 5
minutes at room temperature. After the solid carboxylic acid had dissolved and the clear
solution turned amber, 97 µmol of amine building block was dissolved in 1 mL of DMF
and added to the reaction flask. All reactions were complete within 20 minutes, as
confirmed by analytical thin layer chromatography (TLC) in 60:40 ethyl acetate/hexanes.
The resulting amide products were extracted into chloroform and washed with water
(twice), sodium bicarbonate (once), and water again (three times). The organic layers
were dried and nuclear magnetic resonance (1H-NMR in CDCl3) was used to ensure
product formation. Individual products (as yellow solids) were isolated using preparative
TLC with a mobile phase of 60:40 ethyl acetate/hexanes followed by extraction from
scraped silica using 50:50 ethyl acetate/methylene chloride. Purity for all thirty-three
compounds was confirmed by 1H-NMR (appendix A). High resolution MS data for all
previously unreported compounds gave the expected mass values with absolute errors
ranging from 0.5 to 13.9 ppm.
(1) 2-(2-chlorophenoxy)-1-(4-(2-nitrophenyl)piperazin-1-yl)ethanone
Yield: 17.9 mg of yellow solid (49%). Rf = 0.56 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.03 (m, 4H), 3.79 (m, 4H), 4.79 (s, 2H), 6.94 (t, 1H), 7.01 (d, 1H),
7.11 (t, 2H), 7.20 (d, 1H), 7.36 (d, 1H), 7.49 (t, 1H), 7.78 (d, 1H). MS (ESI+):
m/z = 376.21 [M+H]+, 378.22 [M+2+H]+.
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(2) 2-(2-fluorophenoxy)-1-(4-(2-nitrophenyl)piperazin-1-yl)ethanone
Yield: 13.3 mg of yellow solid (35%). Rf = 0.63 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.05 (t, 4H), 3.78 (t, 4H), 4.78 (s, 2H), 6.95 (m, 1H), 7.08 (m, 5H),
7.50 (t, 1H), 7.78 (d, 1H). MS (ESI+): m/z = 360.23 [M+H]+.
(3) 1-(4-(2-nitrophenyl)piperazin-1-yl)-2-(2-(trifluoromethyl)phenoxy)ethanone
Yield: 10.3 mg of yellow solid (26%). Rf = 0.65 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.00 (t, 4H), 3.78 (m, 4H), 4.82 (s, 2H), 7.10 (m, 4H), 7.49 (t, 2H),
7.58 (d, 1H), 7.78 (d, 1H). MS (ESI+): m/z = 410.19 [M+H]+.
(4) 2-(3-chlorophenoxy)-1-(4-(2-nitrophenyl)piperazin-1-yl)ethanone
Yield: 16.0 mg of yellow solid (44%). Rf = 0.69 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.04 (t, 4H), 3.74 (dt, 4H), 4.70 (s, 2H), 6.84 (d, 1H), 6.96 (dt, 2H),
7.12 (m, 2H), 7.19 (d, 1H), 7.50 (t, 1H), 7.78 (d, 1H). MS (ESI+): m/z = 376.22 [M+H]+,
378.23 [M+2+H]+.
(5) 2-(3-fluorophenoxy)-1-(4-(2-nitrophenyl)piperazin-1-yl)ethanone
Yield: 15.6 mg of yellow solid (41%). Rf = 0.69 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.04 (t, 4H), 3.74 (dt, 4H), 4.70 (s, 2H), 6.7 (m, 3H), 7.12 (m, 2H),
7.35 (bs, 1H), 7.50 (t, 1H), 7.78 (d, 1H). MS (ESI+): m/z = 360.21 [M+H]+.
(6) 1-(4-(2-nitrophenyl)piperazin-1-yl)-2-(3-(trifluoromethyl)phenoxy)ethanone
Yield: 11.1 mg of yellow solid (28%). Rf = 0.76 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.04 (t, 4H), 3.75 (dt, 4H), 4.76 (s, 2H), 7.13 (m, 4H), 7.34 (s, 1H),
7.40 (t, 1H), 7.50 (t, 1H), 7.79 (d, 1H). MS (ESI+): m/z = 410.19 [M+H]+.
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(7) 2-(4-chlorophenoxy)-1-(4-(2-nitrophenyl)piperazin-1-yl)ethanone
Yield: 13.0 mg of yellow solid (36%). Rf = 0.70 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.02 (t, 4H), 3.74 (dt, 4H), 4.70 (s, 2H), 6.88 (dt, 2H), 7.12 (t, 2H),
7.24 (d, 2H), 7.50 (t, 1H), 7.79 (d, 1H). MS (ESI+): m/z = 376.20 [M+H]+, 378.15
[M+2+H]+.
(8) 2-(4-fluorophenoxy)-1-(4-(2-nitrophenyl)piperazin-1-yl)ethanone
Yield: 12.2 mg of yellow solid (32%). Rf = 0.60 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.02 (t, 4H), 3.75 (dt, 4H), 4.68 (s, 2H), 6.89 (m, 2H), 6.97 (t, 2H),
7.12 (t, 2H), 7.50 (t, 1H), 7.79 (d, 1H). MS (ESI+): m/z = 360.24 [M+H]+.
(9) 1-(4-(2-nitrophenyl)piperazin-1-yl)-2-(4-(trifluoromethyl)phenoxy)ethanone
Yield: 12.3 mg of yellow solid (31%). Rf = 0.62 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.03 (t, 4H), 3.75 (dt, 4H), 4.77 (s, 2H), 7.02 (d, 2H), 7.13 (t, 2H),
7.49 (d, 1H), 7.55 (d, 2H), 7.79 (d, 1H). MS (ESI+): m/z = 410.20 [M+H]+.
(10) 2-(2,4-dichlorophenoxy)-1-(4-(2-nitrophenyl)piperazin-1-yl)ethanone
Yield: 12.1 mg of yellow solid (30%). Rf = 0.56 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.03 (t, 4H), 3.76 (q, 4H), 4.78 (s, 2H), 6.95 (d, 1H), 7.10 (d, 2H),
7.18 (dd, 1H), 7.40 (d, 1H), 7.50 (t, 1H), 7.79 (d, 1H). MS (ESI+): m/z = 410.24 [M+H]+,
412.19 [M+2+H]+, 414.14 [M+4+H]+.
(11) 2-(3,5-dichlorophenoxy)-1-(4-(2-nitrophenyl)piperazin-1-yl)ethanone
Yield: 7.2 mg of yellow solid (18%). Rf = 0.56 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.06 (t, 4H), 3.73 (dt, 4H), 4.69 (s, 2H), 6.85 (d, 2H), 7.00 (t, 1H),
7.14 (m, 2H), 7.52 (t, 1H), 7.80 (d, 1H). MS (ESI+): m/z = 410.09 [M+H]+, 412.15
[M+2+H]+, 414.10 [M+4+H]+.
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(12) 2-(2-chlorophenoxy)-1-(4-(3-nitrophenyl)piperazin-1-yl)ethanone
Yield: 10.1 mg of yellow solid (28%). Rf = 0.55 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.26 (dt, 4H), 3.83 (dt, 4H), 4.82 (s, 2H), 6.98 (m, 2H), 7.18 (t, 2H),
7.39 (t, 2H), 7.69 (m, 2H). MS (ESI+): m/z = 376.24 [M+H]+, 378.17 [M+2+H]+.
(13) 2-(2-fluorophenoxy)-1-(4-(3-nitrophenyl)piperazin-1-yl)ethanone
Yield: 14.2 mg of yellow solid (37%). Rf = 0.59 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.27 (m, 4H), 3.82 (q, 4H), 4.80 (s, 2H), 6.96 (m, 1H), 7.08 (m, 3H),
7.19 (d, 1H), 7.39 (t, 1H), 7.70 (m, 2H). MS (ESI+): m/z = 360.25 [M+H]+.
(14) 1-(4-(3-nitrophenyl)piperazin-1-yl)-2-(2-(trifluoromethyl)phenoxy)ethanone
Yield: 15.4 mg of yellow solid (39%). Rf = 0.75 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.23 (t, 4H), 3.81 (dt, 4H), 4.84 (s, 2H), 7.12 (m, 3H), 7.38 (t, 1H),
7.50 (t, 1H), 7.59 (d, 1H), 7.69 (m, 2H). MS (ESI+): m/z = 410.22 [M+H]+.
(15) 2-(3-chlorophenoxy)-1-(4-(3-nitrophenyl)piperazin-1-yl)ethanone
Yield: 15.3 mg of yellow solid (42%). Rf = 0.58 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.27 (q, 4H), 3.78 (m, 4H), 4.72 (s, 2H), 6.85 (d, 1H), 6.96 (d, 2H),
7.18 (m, 2H), 7.40 (t, 1H), 7.70 (m, 2H). MS (ESI+): m/z = 376.20 [M+H]+, 378.14
[M+2+H]+.
(16) 2-(3-fluorophenoxy)-1-(4-(3-nitrophenyl)piperazin-1-yl)ethanone
Yield: 10.0 mg of yellow solid (26%). Rf = 0.55 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.03 (t, 4H), 3.75 (dt, 4H), 4.70 (s, 2H), 6.69 (m, 3H), 7.12 (t, 2H),
7.35 (s, 1H), 7.50 (t, 1H), 7.79 (d, 1H). MS (ESI+): m/z = 360.17 [M+H]+.
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(17) 1-(4-(3-nitrophenyl)piperazin-1-yl)-2-(3-(trifluoromethyl)phenoxy)ethanone
Yield: 10.8 mg of yellow solid (27%). Rf = 0.73 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.05 (t, 4H), 3.75 (dt, 4H), 4.76 (s, 2H), 7.13 (m, 4H), 7.34 (s, 1H),
7.41 (t, 1H), 7.50 (t, 1H), 7.79 (d, 1H). MS (ESI+): m/z = 410.28 [M+H]+.
(18) 2-(4-chlorophenoxy)-1-(4-(3-nitrophenyl)piperazin-1-yl)ethanone
Yield: 10.7 mg of yellow solid (29%). Rf = 0.55 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.27 (q, 4H), 3.78 (q, 4H), 4.72 (s, 2H), 6.89 (d, 2H), 7.17 (d, 1H),
7.22 (s, 1H), 7.25 (s, 1H), 7.39 (t, 1H), 7.70 (m, 2H). MS (ESI+): m/z = 376.22 [M+H]+,
378.22 [M+2+H]+.
(19) 2-(4-fluorophenoxy)-1-(4-(3-nitrophenyl)piperazin-1-yl)ethanone
Yield: 12.3 mg of yellow solid (32%). Rf = 0.52 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.26 (q, 4H), 3.79 (q, 4H), 4.71 (s, 2H), 6.94 (m, 4H), 7.17 (d, 1H),
7.39 (t, 1H), 7.70 (m, 2H). MS (ESI+): m/z = 360.24 [M+H]+.
(20) 1-(4-(3-nitrophenyl)piperazin-1-yl)-2-(4-(trifluoromethyl)phenoxy)ethanone
Yield: 12.4 mg of yellow solid (31%). Rf = 0.66 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.27 (q, 4H), 3.79 (m, 4H), 4.79 (s, 2H), 7.03 (d, 2H), 7.17 (d, 1H),
7.40 (d, 1H), 7.40 (t, 1H), 7.56 (d, 2H), 7.70 (m, 2H). MS (ESI+): m/z = 410.21 [M+H]+.
(21) 2-(2,4-dichlorophenoxy)-1-(4-(3-nitrophenyl)piperazin-1-yl)ethanone
Yield: 14.1 mg of yellow solid (35%). Rf = 0.70 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.26 (m, 4H), 3.81 (m, 4H), 4.80 (s, 2H), 6.96 (d, 1H), 7.18 (m, 2H),
7.38 (m, 2H), 7.70 (m, 2H). MS (ESI+): m/z = 410.14 [M+H]+, 412.11 [M+2+H]+, 414.10
[M+4+H]+.
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(22) 2-(3,5-dichlorophenoxy)-1-(4-(3-nitrophenyl)piperazin-1-yl)ethanone
Yield: 10.3 mg of yellow solid (26%). Rf = 0.61 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.29 (q, 4H), 3.77 (dt, 4H), 4.72 (s, 2H), 6.86 (d, 2H), 7.00 (t, 1H),
7.19 (d, 1H), 7.40 (t, 1H), 7.71 (m, 2H). MS (ESI+): m/z = 410.09 [M+H]+, 412.19
[M+2+H]+, 413.99 [M+4+H]+. Purity (ELSD): >99%.
(23) 2-(2-chlorophenoxy)-1-(4-(4-nitrophenyl)piperazin-1-yl)ethanone
Yield: 8.6 mg of yellow solid (24%). Rf = 0.00 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.24 (m, 4H), 3.82 (dt, 4H), 4.81 (s, 2H), 6.81 (d, 2H), 6.98 (m, 2H),
7.20 (d, 1H), 7.37 (d, 1H), 8.12 (d, 2H). MS (ESI+): m/z = 376.18 [M+H]+, 378.04
[M+2+H]+.
(24) 2-(2-fluorophenoxy)-1-(4-(4-nitrophenyl)piperazin-1-yl)ethanone
Yield: 7.1 mg of yellow solid (37%). Rf = 0.17 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.44 (m, 4H), 3.83 (m, 4H), 4.80 (s, 2H), 6.86 (d, 2H), 6.96 (m, 1H),
7.08 (m, 3H), 8.14 (d, 2H). MS (ESI+): m/z = 360.24 [M+H]+.
(25) 1-(4-(4-nitrophenyl)piperazin-1-yl)-2-(2-(trifluoromethyl)phenoxy)ethanone
Yield: 7.5 mg of yellow solid (19%). Rf = 0.54 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.39 (t, 4H), 3.81 (dt, 4H), 4.84 (s, 2H), 6.80 (d, 2H), 7.09 (q, 2H),
7.50 (t, 1H), 7.59 (d, 1H), 8.12 (d, 2H). MS (ESI+): m/z = 410.28 [M+H]+.
(26) 2-(3-chlorophenoxy)-1-(4-(4-nitrophenyl)piperazin-1-yl)ethanone
Yield: 4.5 mg of yellow solid (12%). Rf = 0.00 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.43 (q, 4H), 3.78 (m, 4H), 4.70 (s, 2H), 6.83 (m, 3H), 6.94 (t, 1H),
6.98 (dq, 1H), 7.20 (d, 1H), 8.14 (d, 2H). MS (ESI+): m/z = 376.29 [M+H]+, 378.23
[M+2+H]+.
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(27) 2-(3-fluorophenoxy)-1-(4-(4-nitrophenyl)piperazin-1-yl)ethanone
Yield: 13.6 mg of yellow solid (35%). Rf = 0.19 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.43 (q, 4H), 3.78 (q, 4H), 4.72 (s, 2H), 6.70 (m, 3H), 6.81 (d, 2H),
7.23 (q, 1H), 8.12 (d, 2H). MS (ESI+): m/z = 360.23 [M+H]+.
(28) 1-(4-(4-nitrophenyl)piperazin-1-yl)-2-(3-(trifluoromethyl)phenoxy)ethanone
Yield: 11.0 mg of yellow solid (28%). Rf = 0.41 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.45 (m, 4H), 3.80 (m, 4H), 4.78 (s, 2H), 6.84 (d, 2H), 7.15 (m, 2H),
7.28 (s, 1H), 7.42 (t, 1H), 8.14 (d, 2H). MS (ESI+): m/z = 410.28 [M+H]+.
(29) 2-(4-chlorophenoxy)-1-(4-(4-nitrophenyl)piperazin-1-yl)ethanone
Yield: 4.3 mg of yellow solid (12%). Rf = 0.49 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.42 (q, 4H), 3.80 (t, 4H), 4.72 (s, 2H), 6.87 (t, 4H), 7.24 (t, 2H), 8.14
(d, 2H). MS (ESI+): m/z = 376.30 [M+H]+, 378.04 [M+2+H]+.
(30) 2-(4-fluorophenoxy)-1-(4-(4-nitrophenyl)piperazin-1-yl)ethanone
Yield: 4.5 mg of yellow solid (12%). Rf = 0.39 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.44 (q, 4H), 3.80 (t, 4H), 4.70 (s, 2H), 6.84 (d, 2H), 6.91 (d, 2H),
6.97 (d, 2H), 8.14 (d, 2H). MS (ESI+): m/z = 360.31 [M+H]+.
(31) 1-(4-(4-nitrophenyl)piperazin-1-yl)-2-(4-(trifluoromethyl)phenoxy)ethanone
Yield: 7.1 mg of yellow solid (18%). Rf = 0.35 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.44 (q, 4H), 3.81 (q, 4H), 4.79 (s, 2H), 6.86 (d, 2H), 7.02 (d, 2H),
7.56 (d, 2H), 8.15 (d, 2H). MS (ESI+): m/z = 410.28 [M+H]+.
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(32) 2-(2,4-dichlorophenoxy)-1-(4-(4-nitrophenyl)piperazin-1-yl)ethanone
Yield: 5.8 mg of yellow solid (15%). Rf = 0.00 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.42 (m, 4H), 3.81 (dt, 4H), 4.80 (s, 2H), 6.81 (d, 2H), 6.95 (d, 1H),
7.19 (dd, 1H), 7.38 (d, 1H), 8.13 (d, 2H). MS (ESI+): m/z = 410.25 [M+H]+, 412.20
[M+2+H]+, 414.25 [M+4+H]+.
(33) 2-(3,5-dichlorophenoxy)-1-(4-(4-nitrophenyl)piperazin-1-yl)ethanone
Yield: 5.2 mg of yellow solid (13%). Rf = 0.00 (ethyl acetate/hexanes 60:40). 1H-NMR
(chloroform-d): δ = 3.46 (q, 4H), 3.77 (dt, 4H), 4.71 (s, 2H), 6.81 (s, 1H), 6.84 (t, 1H),
6.85 (d, 2H), 7.00 (t, 1H), 8.14 (d, 2H). MS (ESI+): m/z = 410.28 [M+H]+, 412.25
[M+2+H]+, 414.25 [M+4+H]+.
2.2.8.2 General Procedure for Carboxy Analog Synthesis: Method A for Ortho and
Meta Analogs
Twenty-two carboxy-containing analogs of GRI392104 (table 2.1) were
synthesized using a two-step reaction (figure 2.3). To a dry round bottom flask, 140
µmol of 2-phenoxyacetic acid building block, 126 µmol of HBTU, and 140 µmol DIPEA
were combined in 4 mL of dichloromethane (DCM) and sonicated for 5 minutes before
transferring 140 µmol of ortho- or meta-carboxy amine building block into the reaction
flask with an additional 1 mL of DCM. This was sonicated for 60 minutes and tracked
with analytical TLC in either 95:5 ethyl acetate/methanol (ortho compounds) or 90:10
chloroform/methanol (meta compounds). Products were then extracted into DCM and
washed with additional water three times before drying the organic layer over sodium
sulfate and filtering into a tared flask and drying to a white crude powder to confirm
synthesis via 1H-NMR (in CDCl3). Once synthesis was confirmed, crude product was
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mixed with silica and additional chloroform before drying the resulting slurry in vacuo
and utilizing flash chromatography to purify the compounds over a 10g Biotage SNAP
column at 25 mL/min unless otherwise mentioned (eluents were the same from analytical
TLC). Purity was confirmed by 1H-NMR before drying the products to a solid white
residue (appendix A). High resolution MS data for all previously unreported compounds
gave the expected mass values with absolute errors ranging from 0.0 to 20.3 ppm. They
were then diluted to 3 mM in DMSO for activity analysis.
2.2.8.3 General Procedure for Carboxy Analog Synthesis: Method B for Para
Analogs
For the remaining eleven para-substituted carboxy-containing analogs of
GRI392104 (table 2.1), the same reagents were combined in a clean, dry flask in 1 mL
dimethyl sulfoxide (DMSO). After 5 minutes of stirring, the clear solution turned amber
and 140 µmol of solid para-carboxy amine building block was dissolved into the reaction
mixture. Over the course of an hour, the amber solution slowly turned cloudy white. The
reactions were worked up in the same manner as the other twenty-two carboxy analogs,
except ethyl acetate was used instead of methylene chloride before synthesis was
confirmed with 1H-NMR. Products were then purified over 10 g Biotage SNAP columns
at 25 mL/min (method C) or via preparative TLC in 92.5:7.5 chloroform/methanol
(method D). Products from method D were extracted in 50:50 ethyl acetate/methylene
chloride and dried to a solid white residue. Purity was confirmed via 1H-NMR before
drying the products to a solid white powder (appendix A). High resolution MS data for
all previously unreported compounds gave the expected mass values with absolute errors
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ranging from 0.0 to 20.3 ppm. Compounds were stored at 3 mM in DMSO for activity
analysis.
(34) 2-(4-(2-(2-chlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 21.8 mg of white solid (46%). Retention time = 1.8 min (method A, 95:5 ethyl
acetate/methanol). 1H-NMR (dimethyl sulfoxide-d): δ = 3.09 (dt, 4H), 3.68 (m, 4H), 5.04
(s, 2H), 6.96 (t, 1H), 7.08 (d, 1H), 7.31 (m, 2H), 7.43 (dd, 1H), 7.53 (d, 1H), 7.64 (t, 1H),
7.95 (d, 1H). MS (ESI-): m/z = 373.13 [M-H]-, 375.13 [M+2-H]-.
(35) 2-(4-(2-(2-fluorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 13.1 mg of white solid (29%). Retention time = 1.7 min (method A, 95:5 ethyl
acetate/methanol). 1H-NMR (dimethyl sulfoxide-d): δ = 3.08 (dt, 4H), 3.67 (t, 4H), 5.00
(s, 2H), 6.95 (m, 1H), 7.10 (s, 1H), 7.12 (t, 1H), 7.22 (q, 1H), 7.34 (t, 1H), 7.54 (d, 1H),
7.63 (t, 1H), 7.95 (d, 1H). MS (ESI-): m/z = 357.15 [M-H]-.
(36) 2-(4-(2-(2-(trifluoromethyl)phenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 13.7 mg of white solid (27%). Retention time = 1.8 min (method A, 95:5 ethyl
acetate/methanol). 1H-NMR (dimethyl sulfoxide-d): δ = 3.08 (dt, 4H), 3.67 (t, 4H), 5.10
(s, 2H), 7.10 (t, 1H), 7.17 (d, 1H), 7.34 (t, 1H), 7.52 (d, 1H), 7.62 (m, 3H), 7.95 (d, 1H).
MS (ESI-): m/z = 407.14 [M-H]-.
(37) 2-(4-(2-(3-chlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 19.0 mg of white solid (40%). Retention time = 1.8 min (method A, 95:5 ethyl
acetate/methanol). 1H-NMR (dimethyl sulfoxide-d): δ = 3.08 (dt, 4H), 3.67 (t, 4H), 4.95
(s, 2H), 6.94 (d, 1H), 7.01 (d, 1H), 7.08 (t, 1H), 7.34 (q, 2H), 7.54 (d, 1H), 7.63 (t, 1H),
7.95 (d, 1H). MS (ESI-): m/z = 373.13 [M-H]-, 375.13 [M+2-H]-.
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(38) 2-(4-(2-(3-fluorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 12.5 mg of white solid (28%). Retention time = 1.7 min (method A, 95:5 ethyl
acetate/methanol). 1H-NMR (dimethyl sulfoxide-d): δ = 3.09 (dt, 4H), 3.67 (t, 4H), 4.93
(s, 2H), 6.83 (m, 3H), 7.33 (m, 2H), 7.55 (d, 1H), 7.64 (d, 1H), 7.95 (d, 1H). MS (ESI-):
m/z = 357.14 [M-H]-.
(39) 2-(4-(2-(3-(trifluoromethyl)phenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 14.7 mg of white solid (29%). Retention time = 1.6 min (method A, 95:5 ethyl
acetate/methanol). 1H-NMR (dimethyl sulfoxide-d): δ = 3.10 (dt, 4H), 3.68 (t, 4H), 5.03
(s, 2H), 7.27 (d, 2H), 7.34 (t, 2H), 7.54 (m, 2H), 7.63 (t, 1H), 7.95 (d, 1H). MS (ESI-):
m/z = 407.16 [M-H]-.
(40) 2-(4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 10.7 mg of white solid (23%). Retention time = 1.7 min (method A, 95:5 ethyl
acetate/methanol). 1H-NMR (dimethyl sulfoxide-d): δ = 3.08 (dt, 4H), 3.67 (t, 4H), 4.92
(s, 2H), 6.99 (d, 2H), 7.34 (m, 3H), 7.54 (d, 1H), 7.63 (t, 1H), 7.95 (d, 1H). MS (ESI-):
m/z = 373.13 [M-H]-, 375.14 [M+2-H]-.
(41) 2-(4-(2-(4-fluorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 8.2 mg of white solid (18%). Retention time = 1.8 min (method A, 95:5 ethyl
acetate/methanol). 1H-NMR (dimethyl sulfoxide-d): δ = 3.08 (dt, 4H), 3.67 (t, 4H), 4.88
(s, 2H), 6.97 (m, 2H), 7.13 (t, 2H), 7.34 (t, 1H), 7.54 (d, 1H), 7.63 (t, 1H), 7.95 (d, 1H).
MS (ESI-): m/z = 357.16 [M-H]-.
(42) 2-(4-(2-(4-(trifluoromethyl)phenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 16.2 mg of white solid (31%). Retention time = 1.6 min (method A, 95:5 ethyl
acetate/methanol). 1H-NMR (dimethyl sulfoxide-d): δ = 3.10 (dt, 4H), 3.67 (t, 4H), 5.05
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(s, 2H), 7.15 (d, 2H), 7.35 (t, 1H), 7.55 (d, 1H), 7.64 (m, 3H), 7.95 (d, 1H). MS (ESI-):
m/z = 407.15 [M-H]-.
(43) 2-(4-(2-(2,4-dichlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 11.1 mg of white solid (22%). Retention time = 1.7 min (method A, 95:5 ethyl
acetate/methanol). 1H-NMR (dimethyl sulfoxide-d): δ = 3.09 (dt, 4H), 3.66 (t, 4H), 5.08
(s, 2H), 7.11 (d, 1H), 7.35 (m, 2H), 7.54 (d, 1H), 7.59 (d, 1H), 7.64 (t, 1H), 7.95 (d, 1H).
MS (ESI-): m/z = 407.11 [M-H]-, 409.11 [M+2-H]-, 4011.15 [M+4-H]-.
(44) 2-(4-(2-(3,5-dichlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 19.8 mg of white solid (38%). Retention time = 1.5 min (method A, 95:5 ethyl
acetate/methanol). 1H-NMR (dimethyl sulfoxide-d): δ = 3.09 (dt, 4H), 3.66 (m, 4H), 5.01
(s, 2H), 7.10 (d, 2H), 7.17 (t, 1H), 7.34 (t, 1H), 7.54 (d, 1H), 7.64 (t, 1H), 7.95 (d, 1H).
MS (ESI-): m/z = 407.09 [M-H]-, 409.10 [M+2-H]-, 411.11 [M+4-H]-.
(45) 3-(4-(2-(2-chlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 12.3 mg of white solid (26%). Retention time = 3.5 min (method A with 20
mL/min flow rate, 90:10 chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.22 (dt,
4H), 3.81 (dt, 4H), 4.82 (s, 2H), 6.93 (t, 1H), 7.02 (d, 1H), 7.12 (d, 1H), 7.20 (d, 1H),
7.36 (d, 2H), 7.61 (s, 2H). MS (ESI-): m/z = 373.15 [M-H]-, 375.16 [M+2-H]-.
(46) 3-(4-(2-(2-fluorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 20.7 mg of white solid (46%). Retention time = 2.5 min (method A, 90:10
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.21 (m, 4H), 3.79 (m, 4H), 4.81 (s,
2H), 6.94 (m, 1H), 7.06 (m, 3H), 7.12 (d, 1H), 7.34 (t, 1H), 7.62 (s, 2H). MS (ESI-): m/z
= 357.18 [M-H]-.
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(47) 3-(4-(2-(2-(trifluoromethyl)phenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 5.0 mg of white solid (10%). Retention time = 2.0 min (method A, 90:10
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.20 (t, 4H), 3.82 (dt, 4H), 4.85 (s,
2H), 7.05 (t, 1H), 7.14 (t, 2H), 7.36 (t, 1H), 7.50 (t, 1H), 7.61 (m, 3H). MS (ESI-): m/z =
407.17 [M-H]-.
(48) 3-(4-(2-(3-chlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 10.1 mg of white solid (21%). Retention time = 1.3 min (method A, 90:10
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.24 (q, 4H), 3.79 (dt, 4H), 4.73 (s,
2H), 6.86 (d, 1H), 6.97 (d, 2H), 7.20 (d, 2H), 7.37 (t, 1H), 7.64 (m, 2H). MS (ESI-): m/z =
373.15 [M-H]-, 375.16 [M+2-H]-.
(49) 3-(4-(2-(3-fluorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 8.1 mg of white solid (18%). Retention time = 2.0 min (method A, 90:10
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.24 (q, 4H), 3.79 (dt, 4H), 4.73 (s,
2H), 6.72 (dd, 3H), 7.19 (dd, 2H), 7.37 (t, 1H), 7.64 (m, 2H). MS (ESI-): m/z = 357.19
[M-H]-.
(50) 3-(4-(2-(3-(trifluoromethyl)phenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 5.0 mg of white solid (10%). Retention time = 1.5 min (method A, 90:10
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.25 (q, 4H), 3.80 (dt, 4H), 4.78 (s,
2H), 7.16 (m, 3H), 7.27 (s, 1H), 7.40 (q, 2H), 7.65 (m, 2H). MS (ESI-): m/z = 407.18 [MH]-.
(51) 3-(4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 5.5 mg of white solid (12%). Retention time = 1.8 min (method A, 90:10
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.23 (q, 4H), 3.79 (m, 4H), 4.72 (s,
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2H), 6.89 (d, 2H), 7.17 (d, 1H), 7.24 (d, 2H), 7.37 (t, 1H), 7.64 (m, 2H). MS (ESI-): m/z =
373.16 [M-H]-, 375.17 [M+2-H]-.
(52) 3-(4-(2-(4-fluorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 7.4 mg of white solid (16%). Retention time = 1.8 min (method A, 90:10
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.19 (m, 4H), 3.75 (m, 4H), 4.70 (s,
2H), 6.91 (d, 2H), 6.97 (t, 2H), 7.11 (d, 1H), 7.33 (t, 1H), 7.60 (m, 2H). MS (ESI-): m/z =
357.21 [M-H]-.
(53) 3-(4-(2-(4-(trifluoromethyl)phenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 9.9 mg of white solid (19%). Retention time = 2.5 min (method A, 90:10
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.25 (m, 4H), 3.80 (dt, 4H), 4.79 (s,
2H), 7.03 (d, 2H), 7.18 (d, 1H), 7.37 (t, 1H), 7.56 (d, 2H), 7.65 (m, 2H). MS (ESI-): m/z =
407.19 [M-H]-.
(54) 3-(4-(2-(2,4-dichlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 7.8 mg of white solid (15%). Retention time = 2.5 min (method A with flow rate
20 mL/min, 90:10 chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.24 (dt, 4H),
3.81 (m, 4H), 4.81 (s, 2H), 6.97 (d, 1H), 7.17 (t, 2H), 7.38 (q, 2H), 7.63 (m, 2H). MS
(ESI-): m/z = 407.13 [M-H]-, 409.14 [M+2-H]-, 411.15 [M+4-H]-.
(55) 3-(4-(2-(3,5-dichlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 6.1 mg of white solid (12%). Retention time = 2.0 min (method A, 90:10
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.26 (q, 4H), 3.78 (dt, 4H), 4.72 (s,
2H), 6.87 (d, 2H), 7.00 (t, 1H), 7.19 (d, 1H), 7.38 (t, 1H), 7.65 (m, 2H). MS (ESI-): m/z =
407.12 [M-H]-, 409.14 [M+2-H]-, 411.16 [M+4-H]-.
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(56) 4-(4-(2-(2-chlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 17.9 mg of white solid (38%). Retention time = 1.8 min (method B and C, 92.5:7.5
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.36 (m, 4H), 3.18 (dt, 4H), 4.82 (s,
2H), 6.86 (d, 2H), 6.94 (t, 1H), 7.02 (d, 1H), 7.21 (d, 1H), 7.37 (d, 1H), 7.98 (d, 2H). MS
(ESI-): m/z = 373.17 [M-H]-, 375.19 [M+2-H]-.
(57) 4-(4-(2-(2-fluorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 7.4 mg of white solid (16%). Rf = 0.46 (method B and D, 92.5:7.5
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.37 (m, 4H), 3.80 (q, 4H), 4.80 (s,
2H), 6.88 (d, 2H), 6.96 (m, 1H), 7.08 (m, 3H), 7.98 (d, 2H) MS (ESI-): m/z = 357.17 [MH]-.
(58) 4-(4-(2-(2-(trifluoromethyl)phenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 4.2 mg of white solid (8%). Rf = 0.32 (method B and D, 92.5:7.5
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.28 (dt, 4H), 3.80 (dt, 4H), 4.84 (s,
2H), 6.85 (d, 2H), 7.06 (t, 1H), 7.13 (d, 1H), 7.50 (t, 1H), 7.59 (d, 1H), 7.98 (d, 2H). MS
(ESI-): m/z = 407.19 [M-H]-.
(59) 4-(4-(2-(3-chlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 13.9 mg of white solid (29%). Retention time = 3.3 min (method B and C, 92.5:7.5
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.32 (dt, 4H), 3.78 (dt, 4H), 4.72 (s,
2H), 6.86 (m, 3H), 6.95 (m, 1H), 6.99 (s, 1H), 7.20 (d, 1H), 7.99 (d, 2H). MS (ESI-): m/z
= 373.22 [M-H]-, 375.13 [M+2-H]-.
(60) 4-(4-(2-(3-fluorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 3.7 mg of white solid (8%). Rf = 0.46 (method B and D, 92.5:7.5
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.36 (q, 4H), 3.77 (m, 4H), 4.73 (s,
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2H), 6.66 (m, 2H), 6.74 (d, 1H), 6.86 (d, 2H), 7.21 (d, 1H), 7.98 (d, 2H). MS (ESI-): m/z
= 357.20 [M-H]-.
(61) 4-(4-(2-(3-(trifluoromethyl)phenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 2.0 mg of white solid (4%). Rf = 0.45 (method B and D, 92.5:7.5
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.70 (m, 4H), 3.76 (m, 4H), 4.77 (s,
2H), 6.86 (d, 2H), 7.15 (m, 2H), 7.27 (s, 1H), 7.41 (t, 1H), 7.97 (d, 2H). MS (ESI-): m/z =
407.22 [M-H]-.
(62) 4-(4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 7.7 mg of white solid (16%). Retention time = 2.0 min (method B and C, 92.5:7.5
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.36 (q, 4H), 3.77 (m, 4H), 4.72 (s,
2H), 6.88 (t, 4H), 7.24 (d, 2H), 7.98 (d, 2H). MS (ESI-): m/z = 373.12 [M-H]-, 375.21
[M+2-H]-.
(63) 4-(4-(2-(4-fluorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 12.4 mg of white solid (27%). Rf = 0.50 (method B and D, 92.5:7.5
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.36 (m, 4H), 3.78 (m, 4H), 4.70 (s,
2H), 6.88 (d, 2H), 6.91 (d, 2H), 6.96 (d, 2H), 7.99 (d, 2H). MS (ESI-): m/z = 357.18 [MH]-.
(64) 4-(4-(2-(4-(trifluoromethyl)phenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 6.6 mg of white solid (13%). Rf = 0.32 (method B and D, 92.5:7.5
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.37 (d, 4H), 3.78 (m, 4H), 4.79 (s,
2H), 6.87 (d, 2H), 7.03 (d, 2H), 7.56 (d, 2H), 7.99 (d, 2H). MS (ESI-): m/z = 407.19 [MH]-.
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(65) 4-(4-(2-(2,4-dichlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 4.8 mg of white solid (9%). Rf = 0.45 (method B and D, 92.5:7.5
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.36 (m, 4H), 3.80 (m, 4H), 4.80 (d,
2H), 6.87 (d, 2H), 6.96 (d, 1H), 7.18 (dd, 1H), 7.38 (d, 1H), 7.99 (d, 2H). MS (ESI-): m/z
= 407.11 [M-H]-, 409.14 [M+2-H]-, 411.21 [M+4-H]-.
(66) 4-(4-(2-(3,5-dichlorophenoxy)acetyl)piperazin-1-yl)benzoic acid
Yield: 5.9 mg of white solid (11%). Rf = 0.36 (method B and D, 92.5:7.5
chloroform/methanol). 1H-NMR (chloroform-d): δ = 3.39 (m, 4H), 3.77 (dt, 4H), 4.71 (s,
2H), 6.86 (s, 2H), 6.89 (d, 2H), 7.00 (t, 1H), 7.99 (d, 2H). MS (ESI-): m/z = 407.15 [MH]-, 409.22 [M+2-H]-, 411.34 [M+4-H]-.
2.3 Results
2.3.1 Protein Model Development
Sequences of both mouse (PDB[89] ID: 3NKM[7]) and rat (PDB ID: 2XR9[6])
ATX were aligned with the FASTA sequence of human ATX (GenBank[99] ID:
Q13822) using MOE (Molecular Operating Environment, Chemical Computing Group,
Montreal, Canada). This analysis confirmed that both mouse and rat ATX have 95%
sequence identity with human ATX. Due to the high similarities either crystal structure
is an appropriate surrogate for the human homologue for modeling. It is worth noting
that the currently available human ATX structures (PDB ID: 4ZG6, 4ZG7, 4ZG9, and
4ZGA) were published after this modeling was developed.[75] However, the mouse and
rat crystal structures were not without limitations. For example, the rat ATX structure
was missing portions of the backbone distant from the active site and hydrophobic
regions, whereas the mouse structure contained several sidechains truncated to alanine
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(methyl) due to unresolved atomic positions (K59, E67, K104, R162, R244, R246, F274,
N398, L458, K462, R549, Q559, R602, E642, and K666). All truncated side chain atoms
were reconstructed to their proper form using the structure preparation feature within
MOE (Molecular Operating Environment, Chemical Computing Group, Montreal,
Canada) and, after alignment and minimization, were similar in orientation to structures
that included these atoms (such as PDB ID: 3WAV[51], all atom RMSD 0.48 Å and
alpha carbon RMSD of 0.19 Å).
2.3.2 Pharmacophore Design
Previously, two potent inhibitors (KM04131 and PF8380) had been docked into
the mouse ATX crystal structure (PDB ID: 3NKM), (figure 2.4)[95]. The modeled
positions of these two hydrophobic tunnel targeted ATX inhibitors were used to generate
a structure-based pharmacophore for ATX inhibition (figure 2.4). An exclusion volume
shape, with a radius of 4 Å, was added to the pharmacophore in order to define the
surface of the receptor. Pharmacophore metrics were calculated for this model using an
internal database of 457[95] compounds of known ATX activity (equations 1-5).[100]
This pharmacophore selected 5 out of 111 actives and 5 out of 346 inactives in that
database, resulting in a 50% yield of actives (number of actives found versus total
number of compounds, equation 1). Other metrics analyzed were sensitivity, specificity,
accuracy, and enrichment (equations 2-5). Abbreviations found in the equations below
include: true positives (TP), false positives (FP), false negatives (FN), true negatives
(TN), number of compounds found by the model (n), total entries in the database (N), and
the number of actives (A). The true positives and false positives are compounds found by
the pharmacophore which are either active or inactive, respectively, whereas true
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negatives and false negatives are compounds which are not found by the pharmacophore
but are inactive or active compounds for ATX inhibition, respectively. The total number
of actives (A) is 111 whereas the total number (N) of entries in the test database is 457
compounds. For yield of actives (equation 1), sensitivity (equation 2), specificity
(equation 3), and accuracy (equation 4) results should be close to 1. However,
enrichment (equation 5) should be above 1 for optimal results. Although this
pharmacophore showed low sensitivity (equation 2), it had high specificity and was used
to search the Genomic Research Institute (GRI) database from the University of
Cincinnati Drug Discovery Center (UC-DDC). A total of 2,090 out of 342,420
compounds were identified as potential hits. For the purposes of this study, active
compounds inhibit ATX activity by 50% or better at 10 µM.
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A)

B)

C)

D)

Figure 2.4: Creation of a Pharmacophore from KM04131 and PF8380. A) Twodimensional structures of known inhibitors, KM04131 and PF8380[49]. B)
KM04131 (black) and PF8380 (teal) docked in mouse autotaxin. C) Overlay of
pharmacophore (orange and green spheres with blue outline) with the docked
compounds. The orange spheres represent groups which can be aromatic or
hydrophobic whereas the green sphere is only hydrophobic. D) Pharmacophore
alone with exclusion volume shape shown in blue outline.

2.3.3 Candidate Inhibitor Modeling
The 2,090 GRI compounds selected as matches to the pharmacophore search of
the GRI database were docked into the 3NKM crystal structure using AutoDock
Vina.[101] Once docked, the exclusion volume shape narrowed the results to 288
compounds that were targeted to the same volume as the starting actives, KM04131 and
PF8380 (figures 2.4 and 2.5). Lipinski’s rules[54] were used to filter the results further to
192 drug-like compounds. In order to sample a wide variety of compounds, the
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Tanimoto coefficient was calculated on the basis of MACCS structural keys to organize
these 192 compounds into 72 clusters (figure 2.6) with ≥55% similarity (or greater). One
representative compound from each cluster was ordered for in vitro screening.

Figure 2.5: Docked Ligands Before (Left) and After (Right) Utilizing the Exclusion
Volume Shape. All 2090 compounds selected by the pharmacophore from the GRI
database were docked into autotaxin (left). The hit-list was narrowed to compounds
that fit into the region of interest with the exclusion volume shape, resulting in 288
compounds (right).

Cluster A

Cluster B

Cluster C

Figure 2.6: Example Clusters Obtained from Utilizing the Tanimoto Coefficient on
the Basis of MACCS Structural Keys. Some compounds clustered into groups of
two or more (like the representatives in Cluster A showing 2 of 85 compounds and
Cluster B showing 2 of 4 compounds) while others were unique in the database and
had no other compounds which were within 55% similarity (such as Cluster C).
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2.3.4 In Vitro Screening
None of the 72 compounds showed assay interference in the form of independent
fluorescence or absorbance or suppression of signals from carboxyfluorescein (primary
activity assay) or para-nitrophenolate (secondary activity assay) (data not shown,
structures appendix B). Because of this, all 72 compounds were assayed first against FS3, then against pNP-TMP. Compounds exhibiting 50% inhibition or greater at 10 µM
with either substrate were considered an active inhibitor of ATX (table 2.2, appendix C).
Initially there appeared to be five active compounds, but upon retesting, the initial
response to GRI 792685 was determined to be a false positive (appendix C). The IC50
values for the 4 active compounds were determined in a dose response assay with FS-3
(table 2.2). Since none of the four compounds showed 50% inhibition or greater of ATXcatalyzed pNP-TMP hydrolysis at 10 µM dose responses were not determined for the
secondary substrate. This differential inhibition pattern suggested that these inhibitors
likely prefer the hydrophobic region of ATX (which is accessed by the larger substrate
FS-3) and are distant from the active site (where the smaller substrate pNP-TMP is
localized.[44] Because GRI 392104 (IC50 4 µM) was the most potent inhibitor, was
tractable to straightforward synthetic approaches, and also from a single compound
cluster, analogs were designed to improve ATX inhibitory activity and explore the
structure-activity relationship.
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Table 2.2: Top GRI Compounds
GRI Compound

FS-3
Inhibition (%)

FS-3 IC50
(μM)

pNP-TMP
Inhibition (%)

65.5 ± 3.2

4.0 ± 0.3

27.7 ± 2.0

59.7 ± 1.7

5.7 ± 0.8

-45.4 ± 2.5

54.1 ± 0.2

6.0 ± 0.5

-6.9 ± 2.0

48.0 ± 4.4

6.6 ± 0.9

7.5 ± 2.4

392104

519441

96880

93694

2.3.5 GRI 392104 Analog Synthesis and Activity Screening
A straightforward two-step approach (figure 2.3) yielded sixty-six analogs of
GRI392104 (table 2.2). Synthesis of these compounds was confirmed by 1H-NMR
before preparative TLC or flash chromatography was used for purification. Liquid
chromatography mass spectrometry, and 1H-NMR and 13C-NMR were used to confirm
the identity and purity of all synthetic targets.
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The 66 compounds in table 2.2 were tested against purified ATX in presence of
either FS-3 (primary activity assay) or pNP-TMP (secondary activity assay) to determine
ATX inhibition (tables 2.3 and 2.4). None of these analogs showed auto-fluorescence or
absorbance at tested wavelengths (data not shown). Of these 66 compounds, 36 were
inhibitors of ATX, showing 50% inhibition or greater against FS-3 at 10 µM. Compound
22 showed significantly improved potency over GRI392104, with an IC50 of 670 nM, a
six-fold improvement over the 4 µM potency of GRI392104 (tables 2.3 and 2.4).
Compounds which inhibit pNP-TMP hydrolysis may bind closer to the active site instead
of in the targeted hydrophobic pocket or they may elicit allosteric effects from the
hydrophobic pocket. Some compounds inhibit both substrates with similar potencies
(such as 55), suggesting they might occupy a binding site closer to the active site.
However, other compounds have drastically decreased potencies against pNP-TMP in
comparison to potency against FS-3 as the substrate (such as 22), indicating these
compounds may bind distant from the active site and may have an allosteric impact on
pNP-TMP hydrolysis.
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Table 2.3: Nitro Analog Activity Data
Analog
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

FS-3 Inhibition
(%)
47.1 ± 4.4
25.6 ± 5.1
50.0 ± 2.7
42.7 ± 1.2
39.5 ± 2.5
49.2 ± 1.5
59.1 ± 1.1
42.4 ± 4.4
72.6 ± 1.5
69.8 ± 0.8
77.7 ± 1.0
41.9 ± 1.7
15.2 ± 5.5
56.4 ± 1.0
62.4 ± 1.7
59.8 ± 2.5
61.9 ± 1.1
62.6 ± 2.1
48.1 ± 3.2
60.4 ± 0.8
73.2 ± 1.7
84.3 ± 0.8
46.1 ± 0.3
35.2 ± 1.4
54.6 ± 6.6
70.6 ± 1.7
63.0 ± 9.2
63.3 ± 0.4
76.0 ± 0.7
65.4 ± 3.2
50.2 ± 1.8
51.8 ± 5.8
63.0 ± 0.4

FS-3 IC50
(μM)
----11.4 ± 4.7
------8.2 ± 0.9
--4.7 ± 1.1
4.1 ± 0.0
3.0 ± 0.1
----6.7 ± 0.6
5.8 ± 0.3
6.2 ± 1.6
4.6 ± 0.1
5.4 ± 0.1
--4.2 ± 0.1
3.4 ± 0.3
0.67 ± 0.1
----9.2 ± 0.6
4.6 ± 0.6
6.6 ± 0.6
4.9 ± 0.2
2.2 ± 0.2
6.4 ± 0.5
8.1 ± 0.6
3.7 ± 0.4
2.3 ± 0.1

pNP-TMP
Inhibition (%)
18.7 ± 0.9
-1.8 ± 4.5
38.2 ± 2.3
24.9 ± 1.0
18.2 ± 3.8
35.4 ± 1.6
38.0 ± 1.3
19.9 ± 3.7
44.7 ± 2.0
37.1 ± 1.3
46.8 ± 1.0
4.9 ± 0.8
-14.7 ± 2.9
7.7 ± 3.3
17.1 ± 1.4
13.3 ± 2.4
14.3 ± 2.9
23.8 ± 2.9
8.9 ± 1.2
30.3 ± 2.0
7.3 ± 2.0
52.1 ± 0.9
-11.9 ± 1.3
-22.7 ± 4.2
-3.7 ± 2.6
15.6 ± 1.2
-14.1 ± 2.3
4.1 ± 1.2
19.9 ± 1.3
-12.1 ± 1.2
26.6 ± 2.0
-14.9 ± 4.7
20.4 ± 0.6
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pNP-TMP
IC50 (μM)
----------------11.3 ± 0.3
--11.4 ± 0.3
--------------------8.9 ± 0.4
-----------------------

Table 2.4: Carboxy Analog Activity Data
Analog
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66

FS-3 Inhibition
(%)
12.1 ± 8.3
-7.6 ± 4.2
17.3 ± 4.5
24.4 ± 3.9
-5.5 ± 8.6
41.3 ± 6.9
74.5 ± 3.2
11.5 ± 11.0
89.1 ± 1.1
27.6 ± 1.5
59.8 ± 4.8
42.0 ± 4.2
10.8 ± 1.7
51.5 ± 1.1
80.0 ± 0.9
55.2 ± 4.7
67.1 ± 3.0
79.8 ± 2.6
58.1 ± 1.4
65.0 ± 4.7
76.1 ± 0.7
54.6 ± 1.9
27.6 ± 2.5
6.1 ± 4.0
10.9 ± 1.8
56.0 ± 0.8
32.3 ± 1.2
43.0 ± 7.1
50.8 ± 0.8
0.9 ± 2.1
46.0 ± 3.1
23.9 ± 4.1
46.7 ± 3.7

FS-3 IC50
(μM)
------------6.0 ± 1.8
--1.8 ± 0.4
--2.2 ± 0.3
----8.1 ± 1.2
2.6 ± 0.2
8.9 ± 1.3
2.2 ± 0.6
3.7 ± 0.2
4.6 ± 0.4
7.5 ± 0.4
2.1 ± 0.1
7.3 ± 0.1
------6.5 ± 0.8
----4.1 ± 0.2
---------

pNP-TMP
Inhibition (%)
1.7 ± 2.0
-5.7 ± 2.7
4.6 ± 2.2
-3.3 ± 2.4
-4.8 ± 4.9
-3.5 ± 3.7
32.1 ± 1.6
-7.2 ± 5.4
43.7 ± 3.2
-7.9 ± 2.8
23.4 ± 4.5
11.5 ± 3.2
10.9 ± 4.1
23.7 ± 2.5
37.1 ± 0.5
30.2 ± 6.8
37.9 ± 3.1
56.6 ± 1.5
41.1 ± 9.3
31.6 ± 3.5
29.5 ± 1.9
56.2 ± 3.4
7.3 ± 3.9
-12.0 ± 6.0
-0.8 ± 2.1
6.8 ± 2.3
-36.5 ± 6.3
-11.4 ± 2.6
19.6 ± 4.3
-6.5 ± 0.6
7.9 ± 4.2
9.7 ± 2.2
27.8 ± 5.4

pNP-TMP
IC50 (μM)
----------------------------------6.2 ± 0.5
------5.2 ± 0.1
-----------------------

Specificity for ATX was determined by testing the twelve inhibitors more potent
than the lead (figure 2.7) against NPP6 and NPP7, the only other NPP family members
that are known to hydrolyze the common substrate LPC. Neither NPP6 nor NPP7
contains a hydrophobic pocket analogous to that of ATX. As such, we anticipated no
effect on NPP6 and NPP7 activity. Indeed, none of these compounds showed inhibition
greater than 16% at 10 µM for either enzyme (appendix D). Additionally, 22 showed
little to no agonist nor antagonist activity with LPA1-5 alone (data not shown) but it did
show modest potentiation of LPA effects at LPA2 (appendix E). These data suggest some
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level of specificity for ATX over related lipid phosphodiesterases and no effect at know
LPA GPCR.

Figure 2.7: Twelve Analogs of GRI392104 with Improved Potency.

2.4 Discussion
ATX has lysophospholipase D activity[1,2] leading to specific GPCR activation
by its product LPA, The ATX-LPA axis has received interest as a drug target[104,105]
due to its role in human disease. Initial headway toward ATX inhibition began with nonspecific metal chelators[43], which inhibited ATX activity when applied in millimolar
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concentrations and which have numerous off target effects. Once LPA and S1P, both
bioactive lipid products of ATX hydrolysis, were identified as feedback inhibitors of
ATX[42], research shifted into inhibitory properties of LPA/S1P analogs.[61,67,106,107]
Although, some of these compounds had promising in vitro potencies, lipids are unlikely
to be orally bioavailable drug candidates according to Lipinski’s rules.[54] Efforts to
generate better drug candidate ATX inhibitors resulted in identification of non-lipid
inhibitors.[44,49,69,107] The first small molecule, non-lipid inhibitor was reported in
2008.[69] Other diverse small molecules were discovered in efforts to improve
potency.[44,45,49,71,77,96,107] Because protein structure and function are closely
related, it is important to understand how molecules bind to ATX in an effort to better
design/identify potent inhibitors. The recently published crystal structures of ATX,
enzyme inhibition kinetics, and molecular docking studies show distinct binding regions
for small molecule ATX inhibitors.[6,7,47,51,75] Small molecule, non-lipid inhibitors
are divided between their interactions with either the polar active site[44,45,75,77] and
the distant hydrophobic domain.[47,51,75,84]
In the present study, a structure-based pharmacophore was generated for the
hydrophobic region of ATX in order to discover novel inhibitor scaffolds which are
likely to show selectivity for ATX over other NPP enzymes (NPP6 and NPP7) that lack
the hydrophobic pocket. These molecules would also be smaller and more rigid than the
relatively large and flexible LPA which would likely prevent their interaction with known
LPA GPCR. After searching a large database of nearly 400,000 compounds, seventy-two
candidate inhibitors were tested with four showing inhibition of ATX (table 2.2). The
most potent and synthetically tractable inhibitor, GRI 392104 (IC50 4 µM) was used as a
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scaffold to explore a structure-activity relationship. Sixty-six analogs (table 2.1) were
synthesized and analyzed for ATX inhibition.
This study used two synthetic substrates to differentiate binding modes without
the need to solve crystallographic structures as both Albers et al. and Kawaguchi et al.
did, which follows a precedent set by Hoeglund et al., Saunders et al., and Fells et
al.[44,51,77,84] FS-3 (Echelon)[53] is a large substrate with increased fluorescence after
hydrolysis by ATX. FS-3 should occupy the entire binding pocket occupied by LPC, the
endogenous substrate, stretching from the polar active site down into the hydrophobic
pocket. Another substrate, 4-nitrophenyl thymidine-5’-monophosphate (pNP-TMP,
Sigma) is synthetic nucleotide which can be hydrolyzed to release 4-nitrophenolate to
absorb light at 405 nm. This smaller substrate, pNP-TMP, should only reside in the polar
active site and not extend into the hydrophobic region. Inhibitors that block FS-3
hydrolysis but not the phosphodiesterase activity of ATX toward pNP-TMP suggests
interactions distant from the polar active site deeper in the hydrophobic region of the
catalytic domain. However, some analogs may still have positive or negative allosteric
effects on pNP-TMP hydrolysis, resulting in either an increase or decrease in ATX
activity on that substrate (for instance, 32 inhibits FS-3 hydrolysis 52% but increases
ATX-catalyzed hydrolysis of pNP-TMP while 22 inhibits ATX activity for both FS-3 and
pNP-TMP to varying degrees).
Thirty-six of the analogs synthesized showed ATX inhibition greater than 50% at
10 µM with FS-3, twelve of which had improved potency over the lead (figure 2.7). Of
these, 22 was sub-micromolar (IC50 670 nM). The 3,5-dichlorophenoxy ring of 22 is
reminiscent of the 3,5-dichlorophenylthiourea ring in Hoeglund 5 (IC50 1.6 µM, figure
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2.8), which was previously shown to be a competitive inhibitor.[44] Like 22, PF-8380
(IC50 2.8 nM, figure 2.8) also has a 3,5-dichloro substituted aromatic ring, but is attached
through a methyl 1-piperazinecarboxylate.[49] Although 22 is similar to both Hoeglund 5
and PF-8380, neither of those scaffolds have a substituted phenoxy ring, which may lend
to the activity of 22. A structure-activity relationship study of PF-8380 also showed the
importance of a 3,5-dichloroaromatic ring, but this study also did not use a substituted
phenoxy ring.[23] Only one of the analogs with the nitro group ortho to the piperazine
ring (11, IC50 3 µM) and two ortho carboxy analogs (42, IC50 1.8 µM and 44, IC50 2.2
µM) showed improved potency over the lead, indicating ortho substitution on the phenyl
piperazine ring may not lead to further improvement. A similar trend was seen with
boronic acid substitution on an aromatic ring by Albers et al. (figure 2.8), where Albers
74 (IC50 > 5 µM) was far less potent than Albers 72 or 73 (IC50 28 nM and 5.7 nM,
respectively) when monitoring choline release from the natural substrate, LPC.[45]
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Inhibitor
Albers 72
Albers 73
Albers 74
Hoeglund 11
Hoeglund 12
Hoeglund 31

R1
H
H
B(OH)2
H
CF3
H

R2
B(OH)2
H
H
CF3
H
H

R3
H
B(OH)2
H
H
H
CF3

IC50 (µM)
0.028
0.0057
>5
900
N/A
1.5

Substrate
LPC
LPC
LPC
FS-3
FS-3
FS-3

Figure 2.8: Previously Discovered Non-lipid ATX Inhibitors.
In general, using a shorter linker than the one in GRI392104 may help limit offtarget effects by reducing flexibility[55] and does not seem to have detrimental effects on
ATX inhibition (32, IC50 3.7 µM is quite similar to GRI392104, IC50 4 µM). It is also of
note that only two of the fluoro-containing compounds (42 and 50, IC50 2.2 µM)
improved potency over the lead. Of the fluoro-containing analogs, both 42 and 50 contain
trifluoromethyl-substituted phenoxy rings in the para and meta positions, respectively.
Ortho substitution on the phenoxy ring decreased potency (tables 2.3 and 2.4), following
a similar pattern noticed by both Albers et al. and Hoeglund et al. during optimization of
disparate lead compounds (figure 2.9).[45,71] All but five of the twelve compounds with
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improved activity over GRI 392104 had dichloro substitution on the phenoxy ring. This
may suggest that, like PF8380 and Hoeglund 5, having a dichloro substitution may
improve potency, as also seen during structure-activity relationship studies of
PF8380.[23] Across the 66 compounds tested, minor changes in structure caused vast
differences in biological activity. These drastic changes are activity cliffs, as described
by both Dimova et al. and Hu et al.[108,109] Figure 2.9 shows a generic structure of
these compounds, highlighting similarities in PF8380 and Hoeglund 5. Based on results
presented here and by extrapolation to related work of others we propose that
optimization of the polar head group of this scaffold can serve as a targeting handle
whereas changes to the non-polar aromatic moiety can be implemented to improve
pharmacokinetics and biological stability – although the 3,5-dichloro moiety is preferred.

Figure 2.9: Common Structure of 1-66, PF8380, and Hoeglund 5. R is O in 1-66
and PF8380 but S in Hoeglund 5.

Although ATX activity is reduced by these inhibitors, they are unlikely to be used
as the lone treatment against ATX-associated diseases without further study in more
complex systems. These compounds may be useful by causing inhibitor-mediated
decreases in ATX activity, which would sensitize tumor cells to radiotherapy[110] and
apoptosis caused by treatments such as Taxol.[111] It is important to explore several
different scaffolds when developing targeted inhibitors because of the high attrition rate
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moving hit compounds through the development pipeline to approved drugs.[90,91] By
diversifying the number of ATX inhibitors, there is greater hope of successfully treating
ATX-related diseases.
2.5 Conclusion
Here we describe a novel ATX inhibitor scaffold that was synthetically modified
to improve potency into the sub-micromolar range. This study also demonstrates that
shortening the carbon linker on this scaffold has no apparent detrimental effect and, in
fact, may be of more use for further development and modification to produce an orally
bioavailable drug. While flexible compounds may be useful for binding to ATX, they
may also adopt additional conformations leading to off-target effects. Out of the sixty-six
new analogs synthesized, twelve showed improved potency with one of those improving
potency into the sub-micromolar range (22, IC50 670 nM versus GRI 392104, IC50 4 µM).
Future endeavors are ongoing to further optimize this lead and to characterize both
pharmacokinetic and pharmacodynamic effects.
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Chapter 3
Expanded Structure-Activity Relationships for Novel Small Molecule Autotaxin
Inhibitors
3.1 Introduction
The first part of the current study focuses on synthetically expanding the
structure-activity relationship (SAR) of autotaxin inhibitors described in chapter 2 to
explore observed activity cliffs. Activity cliffs are vast differences in biological activity
when minor changes in structure are employed.[108] Changing from a nitro group to a
carboxylate on the phenyl piperazine ring dropped activity eleven fold. Exploring
different groups in this position may lead to a deeper understanding of electronic changes
on the ring and interactions with the protein structure. To choose the head groups for
analogs 67 through 71, inspiration as taken from the work of Hammett in 1937. He
described linear free energy relationships due to changes in substitution on aromatic
rings.[112] Although the present work does not analyze reactions, but rather interactions
of small molecules with protein structure, there may still be a correlation between
changes in aromatic ring substitution and observed biological activity.
An expanded structure-activity relationship was undertaken for the most potent
autotaxin inhibitor from Chapter 2. This was done to explore modification to the
substituted phenylpiperazine ring in efforts to explain activity differences between 22 and
the carboxylate analog, 55, which had a decreased potency (IC50 670 nM for 22 versus
7300 nM for 55). These compounds are classified as 67 through 71 (figure 3.2). These
groups were chosen to have a range of Hammett σm values between the nitro group of 22
(σm = 0.71) and the carboxylate group of 55 (σm = -0.10). Hammett values were taken
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from Hansch et al.[113] It was predicted that 67 would have a similar activity to 22, but
perhaps not be as potent of an inhibitor because it is an uncharged polar head group.
Analog 68 was also predicted to behave in a similar manner, but not be as potent as 67
because the chlorine head group is not as electron-withdrawing as either the nitro group
of 22 or the trifluoromethyl group of 67. Both 69 and 70 have the same σm value (0.12),
but the phenolic group on 69 is a hydrogen bond donor and acceptor whereas the
methoxy group on 70 is only a hydrogen bond acceptor. This difference could give
insight into whether it may be better to have a hydrogen bond donor or acceptor in the
scaffold. Analog 71 was important to show what activity may be like without
substitution on the ring, if activity would be decreased compared to analogs with polar or
non-polar groups on the ring.

Number
67
68
69
70
71

X
CF3
Cl
OH
OCH3
H

Hammett σm Value
0.43
0.37
0.12
0.12
0.00

Figure 3.1: Synthetic Scheme to Make Analogs of 22 and 55. Activation of the
carboxylic acid requires O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium
hexafluorophosphate (HBTU) with diisopropylethylamine (DIPEA).
A high throughput screen of 10,000 compounds using the Genomic Research
Institute (GRI) database revealed several potent inhibitors of ATX, including the four
previous compounds described by Fells et al.[84] Another molecule found in this screen
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was GRI 182135 (IC50 154 nM when FS-3 was used as a substrate). As seen in figure
3.2, GRI 182135 and Ragle 22 share a common core, despite the fact that GRI 182135 is
four times more potent than 22 (IC50 670 nM). To understand this activity difference,
another SAR expansion was undertaken to understand what structural differences were
important.

Figure 3.2: Comparison of Known ATX Inhibitors, GRI 182135 and Ragle 22.
Structures of the compounds designed for the SAR expansion for GRI 182135 and
Ragle 22 can be found in figure 3.3. In addition to remaking GRI 182135, a shorter
version of this compound was designed (73) to see if the activity would be similar to that
of GRI 182135, following the trend seen in chapter 2 going from GRI 392104 (IC50 4
μM) to 32 (IC50 3.7 μM). Reducing the linker length reduces flexibility, which could
lead to improved specificity, as mentioned in chapter 2 and Veber et al.[55] As discussed
in chapter 2, the 3,5-dichloro moiety on 22 has been a common feature in several small
molecule ATX inhibitors. Combining this group with the GRI 182135 head group lead to
74, which may be more potent than GRI 182135. Although this dichloro substitution
seems the most favored modification for analogs such as 22, compound 75 was designed
to see if perhaps the 4-chloro-2-methyl substitution showed improved activity compared
to 22, though it would not be expected to have improved potency if the 3,5-dichloro
moiety is preferred. The last compound in this study is 77, which was designed to see if
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adding the extra carbonyl from the GRI 182135 scaffold to 22 would improve potency by
adding an additional hydrogen bonding partner. Understanding how these molecular
changes alter biological activity will prove useful to explore observed activity cliffs.

Number
GRI 182135
73
74

L
3
1
1

X1
CH3
CH3
H

X2
H
H
Cl

X3
Cl
Cl
H

X4
H
H
Cl

Figure 3.3: Synthetic Plans for Generation of 72 through 77, Analogs of 22 and GRI
182135. Activation of the carboxylic acid requires O-(benzotriazol-1-yl)-N,N,N’,N’tetramethyluronium hexafluorophosphate (HBTU) with diisopropylethylamine
(DIPEA).
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3.2 Experimental Methods
3.2.1 Synthesis of Ragle 22 and 55 Analogs
Analogs 67 through 71 were synthesized in a simple two-step reaction. To a dry
round bottom flask, 140 µmol of 3,5-dichlorophenoxyacetic acid, 140 µmol of HBTU
(O-(benzotriazol-1-yl)-N, N, N’,N’-tetramethyluronium hexafluorophosphate) and 140
µmol of N,N-diisopropylethylamine (DIPEA) were combined in 3 mL dry
dichloromethane (DCM) and sonicated for 5 minutes. After the solid carboxylic acid
dissolved and the clear solution turned amber, 280 µmol of amine building block was
dissolved into the reaction mixture and allowed to react for an hour and tracked by thin
layer chromatography (TLC) in 9:1 chloroform / methanol. The reaction was terminated
with the addition of 10 mL water. The amide products were then extracted into DCM
and washed with water (three times). The organic layers were dried over sodium sulfate
and filtered into a tared flask and synthesis was confirmed via 1H-NMR (in CDCl3).
Once product formation was confirmed, preparative TLC was run in 9:1 chloroform /
methanol and the product band was extracted with 1:1 ethyl acetate / dichloromethane
and dried to a solid. Purity for all five compounds was confirmed by the lack of
contaminating peaks on 1H-NMR (appendix F). Pure products were then dried and
diluted to 3 mM in DMSO for activity analysis.
(67) 2-(3,5-dichlorophenoxy)-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1yl)ethanone
Yield: 21.4 mg of white powder (34%). Rf = 0.81 (9:1 chloroform: methanol). 1H-NMR
(chloroform-d): δ = 7.38 (t, 1H), 7.11 (m, 3H), 7.00 (t, 1H), 6.86 (d, 2H), 4.71 (s, 2H),
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3.76 (dt, 4H), 3.23 (q, 4H). MS (ESI+): m/z = 433.14 [M+H]+, 435.11 [M+2+H]+, 437.10
[M+4+H]+.
(68) 1-(4-(3-chlorophenyl)piperazin-1-yl)-2-(3,5-dichlorophenoxy)ethanone
Yield: 15.6 mg white solid (29%). Rf = 0.89 (9:1 chloroform: methanol). 1H-NMR
(chloroform-d): δ = 7.19 (t, 1H), 7.00 (t, 1H), 6.90 (t, 1H), 6.84 (m, 4H), 4.70 (s, 1H),
3.74 (dt, 4H), 3.19 (q, 4H). MS (ESI+): m/z = 399.15 [M+H]+, 401.01 [M+2+H]+, 403.12
[M+4+H]+, 405.14 [M+6+H]+, 407.14 [M+8+H]+.
(69) 2-(3,5-dichlorophenoxy)-1-(4-(3-hydroxyphenyl)piperazin-1-yl)ethanone
Yield: 12.9 mg of tan oil (24%).Rf = 0.79 (9:1 chloroform: methanol). 1H-NMR
(chloroform-d): δ = 7.12 (t, 1H), 7.00 (t, 1H), 6.85 (d, 2H), 6.45 (m, 3H), 4.70 (s, 2H),
3.73 (dt, 4H), 3.17 (q, 4H). MS (ESI-): m/z = 379.25 [M-H]-, 381.27 [M+2-H]-, 383.26
[M+4-H]-.
(70) 2-(3,5-dichlorophenoxy)-1-(4-(3-methoxyphenyl)piperazin-1-yl)ethanone
Yield: 15 mg of oily white solid (27%). Rf = 0.91 (9:1 chloroform: methanol). 1H-NMR
(chloroform-d): δ = 7.19 (t, 1H), 6.99 (s, 1H), 6.85 (s, 1H), 6.54 (d, 1H), 6.46 (d, 2H),
4.70 (s, 2H), 3.78 (s, 3H), 3.74 (dt, 4H), 3.18 (q, 4H). MS (ESI+): m/z = 395.25 [M+H]+,
397.33 [M+2+H]+, 399.33 [M+4+H]+.
(71) 2-(3,5-dichlorophenoxy)-1-(4-phenylpiperazin-1-yl)ethanone
Yield: 13.2 mg of pink powder (26%). Rf = 0.85 (9:1 chloroform: methanol). 1H-NMR
(chloroform-d): δ = 7.29 (t, 2H), 6.99 (t, 1H), 6.95 (d, 2H), 6.86 (d, 2H), 4.70 (s, 2H),
3.75 (dt, 4H), 3.18 (q, 4H). MS (ESI+): m/z = 365.25 [M+H]+, 367.25 [M+2+H]+, 369.25
[M+4+H]+.

75

3.2.2 Synthetic Procedure to Bridge SAR Gap from 22 to GRI 182135
1

H-NMR spectra for compounds 72 through 77 and the remade GRI 182135 can

be found in appendix F.
Analog 72 (starting material for GRI 182135, 73, and 74) was synthesized in a
simple two-step reaction. To a dry round bottom flask, 1120 µmol of piperazine was
dissolved in 1 mL of dimethyl sulfoxide (DMSO). In a separate flask, 560 µmol of 5chlorovanillic acid, 560 µmol HBTU, and 560 µmol of DIPEA were combined in 1 mL
DMSO, creating a dark orange solution within five minutes of stirring. This dark orange
solution was added dropwise to the clear piperazine solution and allowed to stir for 30
minutes while tracking the reaction with TLC (eluent was 9:1 chloroform / methanol).
The reaction was quenched with 20 mL of water and dried in vacuo and product synthesis
was confirmed via mass spectrometry. It was then mixed with alumina and chloroform
before drying the resulting slurry in vacuo and utilizing flash chromatography to purify
the compound over a 40 g alumina column with a 30 mL/min flow rate with 90:10:2
chloroform / methanol / ammonium hydroxide. Purity was confirmed by 1H-NMR before
drying to a white solid. It was then diluted into DMSO and fractionated for synthesis of
analogs GRI 182135, 73, and 74.
(72) (3-chloro-4-hydroxy-5-methoxyphenyl)(piperazin-1-yl)methanone
Yield: 99.2 mg of white solid (33%). Retention time = 5-10 min (90:10:2 chloroform:
methanol: ammonium hydroxide). 1H-NMR (d6-DMSO): δ = 6.95 (d, 2H), 3.85 (s, 3H),
3.42 (t, 4H), 2.69 (t, 4H). MS (ESI+): m/z = 271.30 [M+H]+, 273.26 [M+2+H]+
GRI 182135 and analog 73 were synthesized in a similar manner with different
reagent amounts. In the first dry round bottom flask, 136 µmol of 72 were dissolved in
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700 µL DMSO. In the second round bottom flask, 150 µmol of each appropriate
carboxylic acid (4-chloro-2-methylphenylbutanoic acid for GRI 182135 and 4-chloro-1methylphenylacetic acid for 73), 150 µmol of HBTU, and 150 µmol of DIPEA were
dissolved in 700 µL DMSO. Product formation was tracked via TLC (eluent 90:10:2
chloroform / methanol / ammonium hydroxide). The reactions were quenched after thirty
minutes with 20 mL of water and extracted with ethyl acetate. The organic layers were
washed three times with water before drying over sodium sulfate and drying in vacuo.
Product formation was confirmed via 1H-NMR for both compounds before purification
over preparative TLC (90:10:2 chloroform / methanol / ammonium hydroxide eluent) and
extracted with 1:1 ethyl acetate / DCM. Purity was confirmed via 1H-NMR for GRI
182135 and 73. They were then diluted to 3 mM in DMSO for activity analysis.
(GRI 182135) 4-(4-chloro-2-methylphenoxy)-1-(4-(3-chloro-4-hydroxy-5methoxybenzoyl)piperazin-1-yl)butan-1-one
Yield: 5.8 mg of white solid (8%). Rf = 0.35 (90:10:2 chloroform: methanol: ammonium
hydroxide). 1H-NMR (chloroform-d): δ = 7.09 (s, 1H), 7.06 (d, 1H), 7.00 (d, 1H), 6.90 (d,
1H), 6.70 (d, 1H), 4.00 (t, 2H), 3.92 (s, 3H), 3.60 (bd, 8H), 2.56 (t, 2H), 2.17 (s, 3H),
2.17 (m, 2H). MS (ESI-): m/z = 479.08 [M-H]-, 481.08 [M+2-H]-, 483.05 [M+4-H]-.
(73) 2-(4-chloro-2-methylphenoxy)-1-(4-(3-chloro-4-hydroxy-5methoxybenzoyl)piperazin-1-yl)ethanone
Yield: 4.3 mg of white solid (6%). Rf = 0.35 (90:10:2 chloroform: methanol: ammonium
hydroxide). 1H-NMR (chloroform-d): δ = 7.12 (d, 1H), 7.08 (d, 1H), 6.99 (d, 1H), 6.90
(d, 1H), 6.77 (d, 1H), 4.71 (s, 1H), 3.92 (s, 3H), 3.61 (bd, 8H), 2.02 (s, 3H). MS (ESI-):
m/z = 451.00 [M-H]-, 453.00 [M+2-H]-, 455.00 [M+4-H]-.
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Analog 74 was synthesized in a similar method to GRI 182135 and analog 73. In
a dry round bottom flask, 94.2 µmol of 72 was dissolved in 500 µL DMSO and allowed
to stir (forming a pale yellow solution). Meanwhile, in a separate round bottom flask,
104 µmol of 3,5-dichlorophenoxyacetic acid, 104 µmol of HBTU, and 104 µmol of
DIPEA were dissolved in 500 µL DMSO and allowed to stir for five minutes forming a
yellow solution. It was then added to the solution of 72 and allowed to stir for thirty
minutes, forming a dark amber solution. Product formation was tracked via TLC (eluent
90:10:2 chloroform / methanol / ammonium hydroxide). After thirty minutes, the product
was worked up and purified in the same manner as GRI 182135 and analog 73. Purity
was confirmed by 1H-NMR before drying to a white solid. It was then diluted to 3 mM
in DMSO for activity analysis.
(74) 1-(4-(3-chloro-4-hydroxy-5-methoxybenzoyl)piperazin-1-yl)-2-(3,5dichlorophenoxy)ethanone
Yield: 7.2 mg of white solid (16%). Rf = 0.44 (90:10:2 chloroform: methanol: ammonium
hydroxide). 1H-NMR (chloroform-d): δ = 7.01 (m, 2H), 6.91 (d, 1H), 6.84 (d, 2H), 4.69
(s, 2H), 3.92 (s, 3H), 3.62 (bd, 8H). MS (ESI-): m/z = 471.00 [M-H]-, 473.00 [M+2-H]-,
475.00 [M+4-H]-, 477.00 [M+6-H]-.
The procedure for synthesis of 75 was the same as that of analogs 67 through 71
except 4-chloro-2-methylphenoxyacetic acid was used as the carboxylic acid starting
material instead of 3,5-dichlorophenoxyacetic acid.
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(75) 2-(4-chloro-2-methylphenoxy)-1-(4-(3-nitrophenyl)piperazin-1-yl)ethanone
Yield: 29.2 mg of metallic gold solid (53%). Rf = 0.87 (9:1 chloroform: methanol). 1HNMR (chloroform-d): δ = 7.69 (m, 2H), 7.40 (t, 1H), 7.12 (m, 3H), 6.78 (d, 1H), 4.73 (s,
2H), 3.79 (q, 4H), 3.26 (q, 4H). MS (ESI+): m/z = 390.33 [M+H]+, 392.33 [M+2+H]+.
Analog 76 (starting material for 77) was synthesized in a similar manner to 72,
using p-nitrobenzoic acid instead of 5-chlorovanillic acid. DMF was used as the solvent
instead of DMSO for synthesis. The reaction was terminated with water and the pH was
adjusted to 11 with dilute sodium hydroxide before extracting into DCM. The organic
layer was washed with water three times and dried over sodium sulfate. Once product
formation was confirmed via 1H-NMR and mass spectrometry, preparative TLC was run
in 9:1 chloroform / methanol and the product band was extracted with methanol and dried
to a solid. Purity was confirmed by the lack of contaminating peaks on 1H-NMR before
drying to a yellow solid. It was then diluted into DMF for synthesis of 77.
(76) (4-nitrophenyl)(piperazin-1-yl)methanone
Yield: 57.7 mg of light yellow solid (44%). Rf = 0.43 (9:1 chloroform: methanol). 1HNMR (chloroform-d): δ = 8.27 (d, 2H), 7.56 (d, 2H), 3.54 (dt, 4H), 2.68 (dd, 4H). MS
(ESI+): m/z = 236.45 [M+H]+.
Analog 77 was synthesized in a similar method to 76 (the starting material). In a
dry round bottom flask, 245 µmol of 77 were dissolved in 1 mL of DMF and allowed to
stir (forming an orange solution). Meanwhile, in a separate round bottom flask, 123
µmol of 3,5-dichlorophenoxyacetic acid, 123 µmol of HBTU, and 123 µmol of DIPEA
were stirred together in 1 mL of DMF for five minutes upon which time the solution
became tan. The tan solution was added dropwise to the orange solution of 76 and
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allowed to react for thirty minutes and tracked on TLC (eluent 9:1 chloroform /
methanol). The reaction was quenched with 20 mL of water and extracted with DCM.
The organic layer was washed three times with additional water and synthesis was
confirmed via 1H-NMR (in CDCl3). Once product formation was confirmed, preparative
TLC was run in 9:1 chloroform / methanol and the product band was extracted with 1:1
ethyl acetate / DCM and dried to a solid. Purity was confirmed by lack of contaminating
peaks on 1H-NMR before drying to a white solid. It was then diluted to 3 mM in DMSO
for activity analysis.
(77) 2-(3,5-dichlorophenoxy)-1-(4-(4-nitrobenzoyl)piperazin-1-yl)ethanone
Yield: 9.5 mg of white solid (18%). Rf = 0.73 (9:1 chloroform: methanol).
1

H-NMR (chloroform-d): δ = 8.30 (d, 2H), 7.57 (d, 2H), 7.01 (t, 1H), 6.84 (s, 2H), 4.69

(s, 2H), 3.61 (bt, 8H). MS (ESI+): m/z = 437.08 [M+H]+, 439.17 [M+2+H]+, 437.08
[M+4+H]+.
3.2.3 Enzyme Expression and Purification
The human FLAG-tagged ATX, NPP6, and NPP7 constructs were expressed and
purified as previously described.[96]
3.2.4 In Vitro Screening
Activity assays utilizing FS-3 and pNP-TMP as substrates were done as described
in Chapter 2, with the exception that the BSA concentration was decreased from 30 to 15
µM in the present study.
3.2.5 ATX Inhibitor Specificity: Testing NPP6/7 Inhibition
Specificity for ATX was determined as described in Chapter 2.
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3.2.6 Protein Model Development
A protein model was made from the mouse ATX crystal structure (PDB ID:
3NKM)[7,89] as described in Chapter 2.
3.2.7 In Silico Candidate Inhibitor Modeling
The Molecular Operating Environment (MOE, Chemical Computing Group,
Montreal, Canada) was used to dock analogs 67 through 71 into the prepared mouse ATX
crystal structure. Compounds 22 and 55, which inspired the Hammett series, were also
docked into ATX. To select the docking site, the mouse crystal structures (PDB ID:
3WAX, 3WAY, 3WAV, 3NKN, 3NKO, 3NKP, 3NKQ, and 3NKR)[7,51] were aligned
and residues which surrounded ligands on the ligand interaction map (not shown) were
chosen (Y82, I167, S169, D171, K208, T209, F210, L213, Y214, L216, A217, N230,
L243, K248, F249, H251, R252, W254, G255, G256, P258, W260, F273, F274, W275,
A304, F305, Y306, E308, D311, H315, H359, D473, and G475). With these residues
selected as the docking site, along with the two zinc ions, the rigid receptor protocol was
used in MOE. The triangle matcher was used with London dG scoring and sixty poses
were initially retained. The MMFF94x forcefield was used for refinement with rescoring
using GBVI/WSA dG and ten final poses were retained.
3.3 Results
3.3.1 In Vitro Screening
None of the 12 compounds screened showed assay interference in the form of
independent fluorescence or absorbance or suppression of signals from
carboxyfluorescein or para-nitrophenolate (data not shown). Because of this, all 12
compounds were assayed first against FS-3, then against pNP-TMP. If the compounds
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showed 50% inhibition or greater at 10 µM with either substrate, it was considered an
active inhibitor of ATX (table 3.1).
Table 3.1: Initial FS-3 and pNP-TMP Results. Analogs 72 and 76 are not included as
they were precursors to later structures. Compounds with starred data were tested in
three separate experience and an average ± standard deviation is listed here. For
individual results, see table 2.
Analog
67
68
69
70
71
GRI
182135
73
74
75
77

FS-3 Inhibition
(%)
16.89 ± 1.02
-49.32 ± 1.28
-10.26 ± 1.29
25.06 ± 0.33
-58.00 ± 0.55

FS-3 IC50
(nM)
------

pNP-TMP
Inhibition (%)
-22.35 ± 0.72
6.67 ± 3.71
9.21 ± 2.13
25.66 ± 1.09
7.36 ± 1.44

pNP-TMP IC50
(nM)
------

103.01 ± 2.44

42 ± 0.82*

88.68 ± 1.43

103 ± 3.21

97.85 ± 1.04
100.86 ± 0.74
33.17 ± 1.37
39.57 ± 5.74

167 ± 11*
55 ± 2.6*
---

69.97 ± 1.59
79.37 ± 0.96
17.26 ± 1.09
12.54 ± 0.51

511 ± 5.06
178 ± 0.681
---

Inconsistent inhibition readings for GRI 182135, analogs 73 and 74 were seen in
subsequent dose response determinations using FS-3 as the substrate. The first two
assays were completed using a BioTek Synergy 2 multi-detection microplate reader
(BioTek Instruments, Winooski, Vermont). The first determination (table 3.2) showed
GRI 182135 had a lower IC50 than when the compound was initially screened (which was
154 nM). The assay was repeated and the potencies increased. The compounds were
then tested on the FlexStation reader (Molecular Devices, San Diego, California),
resulting in potencies between the initial two determined for GRI 182135 and 74, but a
higher potency for 73.
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Table 3.2: FS-3 Dose Response Determinations for GRI 182135, 73, and 74. The first
and second FS-3 dose response determinations were done on a BioTek Synergy 2
plate reader. The third determination was completed on a FlexStation reader.
Analog
GRI 182135
73
74

First IC50 (nM)
72 ± 1
195 ± 7
73 ± 2

Second IC50 (nM)
20 ± 1
88 ± 4
35 ± 4

Third IC50 (nM)
35 ± 0.47
217 ± 22
58 ± 1.7

3.3.2 ATX Inhibitor Specificity: Testing NPP6/7 Inhibition
Specificity for ATX was determined by testing the three potent inhibitors (GRI
182135, 73, and 74) against the other members of the NPP family which can hydrolyze
lipids, NPP6 and NPP7. Neither of these two enzymes contains a hydrophobic pocket
similar to ATX[114], so if these inhibitors bind in that pocket, they should not
significantly inhibit NPP6/7-mediated hydrolysis of pNPPC. Indeed, none of these
compounds showed inhibition greater than 3% at 10 µM for either enzyme (appendix G).
However, it is worth noting that all three compounds showed some stimulation (20-30%)
of NPP7-catalyzed hydrolysis of pNPPC.
3.3.3 In Silico Candidate Inhibitor Modeling
None of these compounds showed improved potency over the lead compounds
from chapter 2, 22 (84% inhibition) and 55 (55% inhibition of ATX-catalyzed hydrolysis
of FS-3 at 10 μM compound). Docking was used to compare analogs 67 through 71 to
compounds 22 and 55.
Once the docking was completed, the top pose for each showed a similar
alignment of the common tail group in the hydrophobic pocket (figure 3.4). However,
the differences in head group interactions lead to slightly different positions for each of
the seven compounds. As seen in figures 3.5 and 3.6, the differences in solvent exposure
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and residue interactions can explain the lack of a Hammett trend, in addition to the head
groups being in different positions within the catalytic domain.

Figure 3.4: Docking Results of 67 through 71 in the Mouse ATX Crystal Structure
(PDB ID: 3NKM).[7,89] Panel A shows the empty active site of mATX with a
cartoon indicating the locations of the polar active site, the hydrophobic tunnel, and
the hydrophobic pocket. Panels B through H show the docked positions of each of the
analogs tested as a black ball-and-stick model (B – 22, C – 55, D – 67, E – 68, F – 69,
G – 70, and H – 71).
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Figure 3.5: Ligand Interaction Maps for 22 and 55 Docked in mATX
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Figure 3.6: Ligand Interaction Maps for 67 through 71 Docked in mATX
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3.4 Discussion
The first of two SAR studies in this chapter explored the activity cliff seen
between 22 (IC50 670 nM) and 55 (IC50 7.3 μM), which were described in chapter 2.
Analogs 67 through 71 were designed as a Hammett series to see if the activity
differences could be explained by alerting the electronic character of the compounds
(figure 3.1).[112,113] However, no linear trend was observed by using the Hammett
constants (figure 3.7). In order to explain the observed biological activity, docking was
used for these molecules, as well as 22 and 55 to see if they occupied the same binding
site within ATX. Docking results (figures 3.4, 3.5, and 3.6) showed the head groups of
each analog occupied slightly different areas within the binding site of ATX, which
would explain why there was no linear Hammett trend. In fact, none of the new analogs
tested had activity improved over the lead compounds. Table 3.3 summarizes the
docking results in terms of biological activity for compounds 67 through 71 as well as 22
and 55. Compounds with higher percent inhibition values generally had interactions with
the protein (via hydrogen bonding to W275, for instance) and polar groups were
surrounded by polar residues. For example, the nitro group of 22 is surrounded by polar
residues and the molecule generally has very little solvent exposure. Compounds with
lower percent inhibition showed increasing solvent exposure and weak to no interactions
with the receptor. For example, the phenolic hydrogen bonding partner on 69 shows no
interaction with surrounding residues and the hydrophobic phenyl ring of 71 is exposed
to solvent. Because these analogs occupy different volumes in the catalytic domain of
ATX, it does not make sense that the biological activity would reflect a linear Hammett
trend, which would be due simply to changing electronic environment.
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Figure 3.7: Graph of Hammett Values versus Percent Inhibition of 22, 55, and 67
through 71. Hammett σm values were taken from the review by Hansch et al.[113]
Table 3.3: Comparison of “Hammett” Analog Activity and Docking Analysis. Percent
inhibition (% inhibition) values are given for 10 μM compound activity against ATXcatalyzed FS-3 hydrolysis. Docking results shown in figures 3.5 and 3.6.
Analog

% Inhibition

22

84.3

55

54.6

70

25.0

67

16.9

69

-10.0

68

-49.3

71

-58.0

Docking Analysis
H-bond to W275 backbone, polar head group surrounded
by polar residues, no significant ligand exposure to solvent
No H-bond to W275, carboxylate is chelating zinc ions in
the active site, low ligand exposure to solvent
H-bond to W275 backbone, polar head group surrounded
by polar residues, light ligand exposure to solvent
H-bond to W275 backbone, trifluoromethyl group near
polar residues, light ligand exposure to solvent
H-bond to W275 backbone, phenolic hydrogen bonding
partner not interacting with any residues, light ligand
exposure to solvent
No H-bond to W275, weak β carbon on L213 interacting
with 3,5-dichloro ring, hydrophobic chlorine is exposed to
solvent
H-bond to W275 backbone, weak ε carbon of K248
interaction with phenyl ring, hydrophobic phenyl ring
exposed to solvent
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Another SAR expansion of the GRI 392104 scaffold was undertaken when the
GRI 182135 scaffold was discovered via collaboration with investigators at University of
Tennessee Health Science Center (UTHSC, figure 3.8).[84] Molecules were designed to
explore the activity gap from Ragle 22 (IC50 670 nM) and GRI 182135 (IC50 154 nM,
figure 3.8). After remaking GRI 182135 for testing in this series, 73 and 74 were made
and analyzed. Analog 73 showed an average IC50 of 167 ± 11 nM, which is very similar
to the longer lead compound. It was thought that if activity was similar to GRI 182135
(as GRI 392104 and 32 showed similar activity), then the shorter compound may be
preferred in future studies as reduced flexibility may improve specificity. Analog 74
combines the head group of GRI 182135 with the tail of 22 into a new compound which
had potency improved over 22 (average IC50 55 ± 2.6 nM for 74 versus 670 ± 100 nM for
22). However, remaking GRI 182135 resulted in improved potency over the initial assay
(average IC50 42 ± 0.82 nM versus IC50 154 nM). Perhaps this discrepancy could, in part,
be due to the fact that the IC50 graphs flattened out at 75% activity instead of 100%
activity for the low concentration range when using the BioTek Synergy 2 plate reader
versus 100% activity when using the FlexStation (figure 3.9, graphs for both 73 and 74
are in appendix H), which would have introduced error in the curve fitting. Although
chapter 2 shows the 3,5-dichloro moiety is what leads to more potent inhibitors with the
GRI 392104 scaffold, analog 75 was tested to ensure the improved activity seen with GRI
182135 is not due to the 4-chloro-2-methyl substitution. In fact, 75 only inhibits ATX
activity 33% at 10 μM when FS-3 is used as the substrate. This agrees with conclusions
reached in chapter 2 that the 3,5-dichloromoiety is important for ATX activity. Analog
77 was tested to see if the additional carbonyl in the GRI 182135 scaffold provided a
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useful hydrogen bonding partner or some other benefit to explain the activity differences
between GRI 182135 and 22. However, 77 only inhibited ATX activity 40% at 10 μM in
the FS-3 assay. Both 75 and 77 show that it is not merely the “C” ring substitution or an
additional carbonyl which is responsible for the activity differences between 22 and GRI
182135. Instead, as pointed out in chapter 2, it is likely the difference in polar
substitution on the “A” ring which provides the differences in potency (figure 3.8).
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Figure 3.8: Structural Comparison of GRI 392104, GRI 182135, and Corresponding
SAR Compounds. Inhibition percentages are reported for the 10 μM concentrations
(highest concentration tested) from the FS-3 assay described above. Potency was
determined for compounds with over 50% inhibition in the FS-3 assay and reported as
an IC50 value. Data for GRI 392104, 22, and 32 is taken from chapter 2. Initial data
for GRI 182135 is taken from Fells et al.[84]
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Structure of GRI 182135
First IC50 Graph (Synergy 2 Plate
Reader)

Third IC50 Graph (FlexStation
Reader)

Second IC50 Graph (Synergy 2 Plate
Reader)

Figure 3.9: FS-3 Dose Response Graphs for GRI 182135
In order to further expand the SAR between 22 and GRI 182135, it would be
important to understand if all three groups on the “A” ring are important for activity.
This could be tested by designing new compounds to see how the number or position of
substituents changes the biological activity, such as those listed in figure 3.10. A longer
version of 74 could also be tested to see if a longer chain length is preferred by this
scaffold. Although there may be concerns as to specificity and flexibility leading to offtarget effects, initial testing showed that GRI 182135 did not necessarily confer inhibition
of NPP6 or NPP7 (appendix G).
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Figure 3.10: Proposed Structures for Further SAR Expansion of GRI 182135
3.5 Conclusion
This work described the expanded structure-activity relationship of a previously
discovered novel scaffold for ATX inhibition. Potencies improved approximately twelve
fold (22 IC50 670 nM versus 74 average IC50 55 nM) in an attempt to explain activity
gaps discovered for this scaffold in chapter 2. While a linear activity relationship was not
discovered for GRI 392104 analogs, activity differences could be explained through
docking analysis. Unfavorable solvent exposure and lack of interactions with the
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receptor decreased ATX inhibition. Additionally, the docked positions of each
compound occupied a slightly different volume within the active site, resulting in an
inability to see a linear Hammett trend for activity. However, new optimization of GRI
182135 is described herein with plans for further expansion to understand the similarities
and differences between 22 and GRI 182135 which are structurally similar but have
different activities. Future endeavors to generate new, potent inhibitors of ATX can also
make use of these scaffolds.
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Chapter 4
Discussion of Findings, Conclusions, and Recommendations
4.1 Discussion of Findings and Conclusions
This work sought to gain a better understanding of structure-activity relationship
between autotaxin (ATX), a ubiquitous enzyme first discovered in cancer, and a subset of
small molecules which inhibit ATX activity.[8,9] Not only did this work demonstrate the
creation and use of one of the first reported structure-based pharmacophores for ATX, but
it was then used to discover a novel inhibitor scaffold (GRI 392104, figure 4.1).[85] This
new scaffold was optimized (from GRI 392104 with an IC50 of 4000 nM to 22, IC50 670
nM) by generating sixty-six compounds, forty-three of which are new compounds (table
2.1). A previously discovered potent inhibitor, GRI 182135, had structural similarities to
GRI 392104 (figure 4.1).[84] Another nine compounds were synthesized to explore these
similarities and differences between the two scaffolds, resulting in seven additional new
compounds (figures 3.1 and 3.3). This makes a total of fifty new compounds developed
over the course of this dissertation. These scaffolds can serve as a branching point for
understanding the changes in SAR landscape for similar small molecule ATX inhibitors
(figures 4.1 and 2.9).
The work described herein has focused on the discovery and structure-activity
relationship (SAR) exploration of a series of small molecule autotaxin inhibitors. These
inhibitors share structural similarities to previously known inhibitors including those
from Hoeglund et al. and PF-8380 (figure 4.1).[44,49] It was observed that these
molecules have a dual-landscape SAR. On one side, there is a polar group where minor
changes can alter the potency of the compounds drastically, leading to activity
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cliffs.[108] However, on the other side of the molecule, it does seem a 3,5-dichloro
moiety is only modestly preferred (as seen with both the PF-8380 SAR studies and the
SAR expansion of GRI 392104, described in both chapters 2 and 3).[23] For instance, 11
(IC50 3 μM) and 33 (IC50 2 μM) are similar in potency to the 2,4-dichloro analogs, 10
(IC50 4 μM) and 32 (IC50 2 μM). This allows two handles for optimization for bringing
scaffolds of this design to the clinical setting (figure 2.9). Alterations to the polar moiety
can improve potency and specificity of the compound while changes to the non-polar end
can be used to optimize pharmacokinetics if necessary, because this region has a
relatively flat SAR landscape.

Figure 4.1: Structural Comparison of Small Molecule ATX Inhibitors in this SAR
Study.
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4.2 Recommendations
The docked positions of potent compounds (figure 4.2) can be corroborated
through site-directed mutagenesis, as shown by Fells et al.[84] All three of the inhibitors
pictured are hydrogen bonding with the backbone of W275 (W274 in human ATX).
Because this is a backbone interaction, mutagenesis would not be informative at this site.
However, the polar groups on the three inhibitors (phenolic OH on 73 and 74 and the
nitro on 22) are within 3.5 Å of the guanidinium R244 (R243 in human ATX).
Mutagenesis of this residue to alanine should decrease the potency of these inhibitors by
removing this polar interaction. Additionally, mutagenesis of this arginine to smaller,
polar residues such as asparagine or serine should show decreased ATX inhibition by
these compounds without changing the polar environment of this region of the enzyme
binding pocket.
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Figure 4.2: Docked Positions of 22, 73, and 74. Potent inhibitors 22 (brown, IC50
670 nM, panel B), 73 (purple, IC50 167 nM, panel C), and 74 (black, panel D, IC50 55
nM) were docked into the model of the mATX crystal structure using MOE. Key
residues are highlighted in panels B, C, and D.
While the previously discussed structure-activity relationships focused on
changing the aromatic substituents on the lead scaffold, the core structure could also be
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explored. Bioorthogonal “click chemistry” could be a quick and effective way to
discover new inhibitors in situ.[115-118] The patent literature has described several
triazole compounds with inhibition of ATX, but these had the triazole as a head group
acting as a bioisostere for other polar head groups such as carboxylates.[82,83] However,
the triazole ring could replace the piperazinyl ring in the core of the lead compound
instead (as shown in figure 4.3). “Click chemistry” can be done in situ by combining
different pieces of known inhibitors (examples figure 4.4) to find optimal combinations
which can result in more potent inhibitors, since the triazoles will only form if the
reagents are in close proximity to one another.[119] Setting this up in a microwell plate
format would allow for screening of multiple combinations and selection of potent
inhibitors, as shown by Lee et al.[120]

Figure 4.3: Example “Click Chemistry” Reaction to Generate New Analogs
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Figure 4.4: Example “Click Chemistry” Reagents to Generate New Inhibitors
Instead of making logical alterations to the newly discovered inhibitor scaffold,
new scaffolds could also be found through computational techniques. A new
pharmacophore can be generated from the docked positions of potent inhibitors (figure
4.2) and used to search a larger database to discover new scaffolds for ATX
inhibition.[97,121] This pharmacophore should include a hydrogen bond acceptor to
interact with the W275 backbone (shown in figure 4.2) as well as a hydrogen bond
acceptor near R244. Additionally, at least one aromatic feature should be included. The
new scaffolds discovered by this pharmacophore would provide new templates for SAR
optimization to expand the diversity of potent ATX inhibitors. Discovering new and
more potent inhibitors will be useful as ATX inhibitors begin to enter clinical trials, as
there is a high attrition rate for drug targeting various diseases.[90-92]
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Appendices
Appendix A: Spectral Information for Analogs 1 through 66.
(1) 2-(2-chlorophenoxy)-1-(4-(2nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.03 (m, 4H),
3.79 (m, 4H), 4.79 (s, 2H), 6.94 (t, 1H), 7.01
(d, 1H), 7.11 (t, 2H), 7.20 (d, 1H), 7.36 (d,
1H), 7.49 (t, 1H), 7.78 (d, 1H). MS (ESI+):
m/z = 376.21 [M+H]+, 378.22 [M+2+H]+.

(2) 2-(2-fluorophenoxy)-1-(4-(2nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.05 (t, 4H),
3.78 (t, 4H), 4.78 (s, 2H), 6.95 (m, 1H), 7.08
(m, 5H), 7.50 (t, 1H), 7.78 (d, 1H). MS
(ESI+): m/z = 360.23 [M+H]+.

(3) 1-(4-(2-nitrophenyl)piperazin-1-yl)-2-(2(trifluoromethyl)phenoxy)ethanone
1
H-NMR (chloroform-d): δ = 3.00 (t, 4H), 3.78
(m, 4H), 4.82 (s, 2H), 7.10 (m, 4H), 7.49 (t,
2H), 7.58 (d, 1H), 7.78 (d, 1H). MS (ESI+):
m/z = 410.19 [M+H]+.
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(4) 2-(3-chlorophenoxy)-1-(4-(2nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.04 (t, 4H),
3.74 (dt, 4H), 4.70 (s, 2H), 6.84 (d, 1H), 6.96
(dt, 2H), 7.12 (m, 2H), 7.19 (d, 1H), 7.50 (t,
1H), 7.78 (d, 1H). MS (ESI+): m/z = 376.22
[M+H]+, 378.23 [M+2+H]+.

(5) 2-(3-fluorophenoxy)-1-(4-(2nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.04 (t, 4H),
3.74 (dt, 4H), 4.70 (s, 2H), 6.7 (m, 3H), 7.12
(m, 2H), 7.35 (bs, 1H), 7.50 (t, 1H), 7.78 (d,
1H). MS (ESI+): m/z = 360.21 [M+H]+.

(6) 1-(4-(2-nitrophenyl)piperazin-1-yl)-2-(3(trifluoromethyl)phenoxy)ethanone
1
H-NMR (chloroform-d): δ = 3.04 (t, 4H),
3.75 (dt, 4H), 4.76 (s, 2H), 7.13 (m, 4H), 7.34
(s, 1H), 7.40 (t, 1H), 7.50 (t, 1H), 7.79 (d, 1H).
MS (ESI+): m/z = 410.19 [M+H]+.
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(7) 2-(4-chlorophenoxy)-1-(4-(2nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.02 (t, 4H),
3.74 (dt, 4H), 4.70 (s, 2H), 6.88 (dt, 2H), 7.12
(t, 2H), 7.24 (d, 2H), 7.50 (t, 1H), 7.79 (d,
1H). MS (ESI+): m/z = 376.20 [M+H]+,
378.15 [M+2+H]+.

(8) 2-(4-fluorophenoxy)-1-(4-(2nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.02 (t, 4H),
3.75 (dt, 4H), 4.68 (s, 2H), 6.89 (m, 2H), 6.97
(t, 2H), 7.12 (t, 2H), 7.50 (t, 1H), 7.79 (d, 1H).
MS (ESI+): m/z = 360.24 [M+H]+.

(9) 1-(4-(2-nitrophenyl)piperazin-1-yl)-2-(4(trifluoromethyl)phenoxy)ethanone
1
H-NMR (chloroform-d): δ = 3.03 (t, 4H),
3.75 (dt, 4H), 4.77 (s, 2H), 7.02 (d, 2H), 7.13
(t, 2H), 7.49 (d, 1H), 7.55 (d, 2H), 7.79 (d,
1H). MS (ESI+): m/z = 410.20 [M+H]+.

114

(10) 2-(2,4-dichlorophenoxy)-1-(4-(2nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.03 (t, 4H),
3.76 (q, 4H), 4.78 (s, 2H), 6.95 (d, 1H), 7.10
(d, 2H), 7.18 (dd, 1H), 7.40 (d, 1H), 7.50 (t,
1H), 7.79 (d, 1H). MS (ESI+): m/z = 410.24
[M+H]+, 412.19 [M+2+H]+, 414.14
[M+4+H]+.

(11) 2-(3,5-dichlorophenoxy)-1-(4-(2nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.06 (t, 4H),
3.73 (dt, 4H), 4.69 (s, 2H), 6.85 (d, 2H), 7.00
(t, 1H), 7.14 (m, 2H), 7.52 (t, 1H), 7.80 (d,
1H). MS (ESI+): m/z = 410.09 [M+H]+,
412.15 [M+2+H]+, 414.10 [M+4+H]+.

(12) 2-(2-chlorophenoxy)-1-(4-(3nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.26 (dt, 4H),
3.83 (dt, 4H), 4.82 (s, 2H), 6.98 (m, 2H), 7.18
(t, 2H), 7.39 (t, 2H), 7.69 (m, 2H). MS
(ESI+): m/z = 376.24 [M+H]+, 378.17
[M+2+H]+.
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(13) 2-(2-fluorophenoxy)-1-(4-(3nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.27 (m, 4H),
3.82 (q, 4H), 4.80 (s, 2H), 6.96 (m, 1H), 7.08
(m, 3H), 7.19 (d, 1H), 7.39 (t, 1H), 7.70 (m,
2H). MS (ESI+): m/z = 360.25 [M+H]+.

(14) 1-(4-(3-nitrophenyl)piperazin-1-yl)-2(2-(trifluoromethyl)phenoxy)ethanone
1
H-NMR (chloroform-d): δ = 3.23 (t, 4H),
3.81 (dt, 4H), 4.84 (s, 2H), 7.12 (m, 3H), 7.38
(t, 1H), 7.50 (t, 1H), 7.59 (d, 1H), 7.69 (m,
2H). MS (ESI+): m/z = 410.22 [M+H]+.

(15) 2-(3-chlorophenoxy)-1-(4-(3nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.27 (q, 4H),
3.78 (m, 4H), 4.72 (s, 2H), 6.85 (d, 1H),
6.96 (d, 2H), 7.18 (m, 2H), 7.40 (t, 1H),
7.70 (m, 2H). MS (ESI+): m/z = 376.20
[M+H]+, 378.14 [M+2+H]+.
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(16) 2-(3-fluorophenoxy)-1-(4-(3nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.03 (t, 4H),
3.75 (dt, 4H), 4.70 (s, 2H), 6.69 (m, 3H),
7.12 (t, 2H), 7.35 (s, 1H), 7.50 (t, 1H), 7.79
(d, 1H). MS (ESI+): m/z = 360.17 [M+H]+.

(17) 1-(4-(3-nitrophenyl)piperazin-1-yl)-2(3-(trifluoromethyl)phenoxy)ethanone
1
H-NMR (chloroform-d): δ = 3.05 (t, 4H),
3.75 (dt, 4H), 4.76 (s, 2H), 7.13 (m, 4H),
7.34 (s, 1H), 7.41 (t, 1H), 7.50 (t, 1H), 7.79
(d, 1H). MS (ESI+): m/z = 410.28 [M+H]+.

(18) 2-(4-chlorophenoxy)-1-(4-(3nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.27 (q, 4H),
3.78 (q, 4H), 4.72 (s, 2H), 6.89 (d, 2H), 7.17
(d, 1H), 7.22 (s, 1H), 7.25 (s, 1H), 7.39 (t,
1H), 7.70 (m, 2H). MS (ESI+): m/z = 376.22
[M+H]+, 378.22 [M+2+H]+.
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(19) 2-(4-fluorophenoxy)-1-(4-(3nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.26 (q, 4H),
3.79 (q, 4H), 4.71 (s, 2H), 6.94 (m, 4H),
7.17 (d, 1H), 7.39 (t, 1H), 7.70 (m, 2H). MS
(ESI+): m/z = 360.24 [M+H]+.

(20) 1-(4-(3-nitrophenyl)piperazin-1-yl)2-(4-(trifluoromethyl)phenoxy)ethanone
1
H-NMR (chloroform-d): δ = 3.27 (q, 4H),
3.79 (m, 4H), 4.79 (s, 2H), 7.03 (d, 2H),
7.17 (d, 1H), 7.40 (d, 1H), 7.40 (t, 1H),
7.56 (d, 2H), 7.70 (m, 2H). MS (ESI+):
m/z = 410.21 [M+H]+.

(21) 2-(2,4-dichlorophenoxy)-1-(4-(3nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.26 (m, 4H),
3.81 (m, 4H), 4.80 (s, 2H), 6.96 (d, 1H), 7.18
(m, 2H), 7.38 (m, 2H), 7.70 (m, 2H). MS
(ESI+): m/z = 410.14 [M+H]+, 412.11
[M+2+H]+, 414.10 [M+4+H]+.
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(22) 2-(3,5-dichlorophenoxy)-1-(4-(3nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.29 (q, 4H),
3.77 (dt, 4H), 4.72 (s, 2H), 6.86 (d, 2H), 7.00
(t, 1H), 7.19 (d, 1H), 7.40 (t, 1H), 7.71 (m,
2H). MS (ESI+): m/z = 410.09 [M+H]+,
412.19 [M+2+H]+, 413.99 [M+4+H]+.
Purity (ELSD): >99%.

(23) 2-(2-chlorophenoxy)-1-(4-(4nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.24 (m, 4H),
3.82 (dt, 4H), 4.81 (s, 2H), 6.81 (d, 2H), 6.98
(m, 2H), 7.20 (d, 1H), 7.37 (d, 1H), 8.12 (d,
2H). MS (ESI+): m/z = 376.18 [M+H]+,
378.04 [M+2+H]+.

(24) 2-(2-fluorophenoxy)-1-(4-(4nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.44 (m, 4H),
3.83 (m, 4H), 4.80 (s, 2H), 6.86 (d, 2H), 6.96
(m, 1H), 7.08 (m, 3H), 8.14 (d, 2H). MS
(ESI+): m/z = 360.24 [M+H]+.
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(25) 1-(4-(4-nitrophenyl)piperazin-1-yl)-2(2-(trifluoromethyl)phenoxy)ethanone
1
H-NMR (chloroform-d): δ = 3.39 (t, 4H),
3.81 (dt, 4H), 4.84 (s, 2H), 6.80 (d, 2H),
7.09 (q, 2H), 7.50 (t, 1H), 7.59 (d, 1H), 8.12
(d, 2H). MS (ESI+): m/z = 410.28 [M+H]+.

(26) 2-(3-chlorophenoxy)-1-(4-(4nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.43 (q, 4H),
3.78 (m, 4H), 4.70 (s, 2H), 6.83 (m, 3H),
6.94 (t, 1H), 6.98 (dq, 1H), 7.20 (d, 1H),
8.14 (d, 2H). MS (ESI+): m/z = 376.29
[M+H]+, 378.23 [M+2+H]+.

(27) 2-(3-fluorophenoxy)-1-(4-(4nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.43 (q, 4H),
3.78 (q, 4H), 4.72 (s, 2H), 6.70 (m, 3H),
6.81 (d, 2H), 7.23 (q, 1H), 8.12 (d, 2H).
MS (ESI+): m/z = 360.23 [M+H]+.
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(28) 1-(4-(4-nitrophenyl)piperazin-1-yl)2-(3-(trifluoromethyl)phenoxy)ethanone
1
H-NMR (chloroform-d): δ = 3.45 (m, 4H),
3.80 (m, 4H), 4.78 (s, 2H), 6.84 (d, 2H),
7.15 (m, 2H), 7.28 (s, 1H), 7.42 (t, 1H),
8.14 (d, 2H). MS (ESI+): m/z = 410.28
[M+H]+.

(29) 2-(4-chlorophenoxy)-1-(4-(4nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.42 (q, 4H),
3.80 (t, 4H), 4.72 (s, 2H), 6.87 (t, 4H), 7.24
(t, 2H), 8.14 (d, 2H). MS (ESI+): m/z =
376.30 [M+H]+, 378.04 [M+2+H]+.

(30) 2-(4-fluorophenoxy)-1-(4-(4nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.44 (q, 4H),
3.80 (t, 4H), 4.70 (s, 2H), 6.84 (d, 2H), 6.91
(d, 2H), 6.97 (d, 2H), 8.14 (d, 2H). MS
(ESI+): m/z = 360.31 [M+H]+.
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(31) 1-(4-(4-nitrophenyl)piperazin-1-yl)-2(4-(trifluoromethyl)phenoxy)ethanone
1
H-NMR (chloroform-d): δ = 3.44 (q, 4H),
3.81 (q, 4H), 4.79 (s, 2H), 6.86 (d, 2H), 7.02
(d, 2H), 7.56 (d, 2H), 8.15 (d, 2H). MS
(ESI+): m/z = 410.28 [M+H]+.

(32) 2-(2,4-dichlorophenoxy)-1-(4-(4nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.42 (m, 4H),
3.81 (dt, 4H), 4.80 (s, 2H), 6.81 (d, 2H),
6.95 (d, 1H), 7.19 (dd, 1H), 7.38 (d, 1H),
8.13 (d, 2H). MS (ESI+): m/z = 410.25
[M+H]+, 412.20 [M+2+H]+, 414.25
[M+4+H]+.

(33) 2-(3,5-dichlorophenoxy)-1-(4-(4nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 3.46 (q, 4H),
3.77 (dt, 4H), 4.71 (s, 2H), 6.81 (s, 1H),
6.84 (t, 1H), 6.85 (d, 2H), 7.00 (t, 1H), 8.14
(d, 2H). MS (ESI+): m/z = 410.28 [M+H]+,
412.25 [M+2+H]+, 414.25 [M+4+H]+.
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(34) 2-(4-(2-(2chlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (dimethyl sulfoxide-d): δ = 3.09 (dt,
4H), 3.68 (m, 4H), 5.04 (s, 2H), 6.96 (t, 1H),
7.08 (d, 1H), 7.31 (m, 2H), 7.43 (dd, 1H), 7.53
(d, 1H), 7.64 (t, 1H), 7.95 (d, 1H). MS (ESI-):
m/z = 373.13 [M-H]-, 375.13 [M+2-H]-.

(35) 2-(4-(2-(2fluorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (dimethyl sulfoxide-d): δ = 3.08
(dt, 4H), 3.67 (t, 4H), 5.00 (s, 2H), 6.95 (m,
1H), 7.10 (s, 1H), 7.12 (t, 1H), 7.22 (q, 1H),
7.34 (t, 1H), 7.54 (d, 1H), 7.63 (t, 1H), 7.95
(d, 1H). MS (ESI-): m/z = 357.15 [M-H]-.

(36) 2-(4-(2-(2(trifluoromethyl)phenoxy)acetyl)piperazin1-yl)benzoic acid
1
H-NMR (dimethyl sulfoxide-d): δ = 3.08 (dt,
4H), 3.67 (t, 4H), 5.10 (s, 2H), 7.10 (t, 1H),
7.17 (d, 1H), 7.34 (t, 1H), 7.52 (d, 1H), 7.62
(m, 3H), 7.95 (d, 1H). MS (ESI-): m/z =
407.14 [M-H]-.
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(37) 2-(4-(2-(3chlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (dimethyl sulfoxide-d): δ = 3.08
(dt, 4H), 3.67 (t, 4H), 4.95 (s, 2H), 6.94 (d,
1H), 7.01 (d, 1H), 7.08 (t, 1H), 7.34 (q, 2H),
7.54 (d, 1H), 7.63 (t, 1H), 7.95 (d, 1H). MS
(ESI-): m/z = 373.13 [M-H]-, 375.13 [M+2H]-.

(38) 2-(4-(2-(3fluorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (dimethyl sulfoxide-d): δ = 3.09 (dt,
4H), 3.67 (t, 4H), 4.93 (s, 2H), 6.83 (m, 3H),
7.33 (m, 2H), 7.55 (d, 1H), 7.64 (d, 1H), 7.95
(d, 1H). MS (ESI-): m/z = 357.14 [M-H]-.

(39) 2-(4-(2-(3(trifluoromethyl)phenoxy)acetyl)piperazin1-yl)benzoic acid
1
H-NMR (dimethyl sulfoxide-d): δ = 3.10 (dt,
4H), 3.68 (t, 4H), 5.03 (s, 2H), 7.27 (d, 2H),
7.34 (t, 2H), 7.54 (m, 2H), 7.63 (t, 1H), 7.95
(d, 1H). MS (ESI-): m/z = 407.16 [M-H]-.
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(40) 2-(4-(2-(4chlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (dimethyl sulfoxide-d): δ = 3.08 (dt,
4H), 3.67 (t, 4H), 4.92 (s, 2H), 6.99 (d, 2H),
7.34 (m, 3H), 7.54 (d, 1H), 7.63 (t, 1H), 7.95
(d, 1H). MS (ESI-): m/z = 373.13 [M-H]-,
375.14 [M+2-H]-.

(41) 2-(4-(2-(4fluorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (dimethyl sulfoxide-d): δ = 3.08 (dt,
4H), 3.67 (t, 4H), 4.88 (s, 2H), 6.97 (m, 2H),
7.13 (t, 2H), 7.34 (t, 1H), 7.54 (d, 1H), 7.63
(t, 1H), 7.95 (d, 1H). MS (ESI-): m/z =
357.16 [M-H]-.

(42) 2-(4-(2-(4(trifluoromethyl)phenoxy)acetyl)piperazin1-yl)benzoic acid
1
H-NMR (dimethyl sulfoxide-d): δ = 3.10 (dt,
4H), 3.67 (t, 4H), 5.05 (s, 2H), 7.15 (d, 2H),
7.35 (t, 1H), 7.55 (d, 1H), 7.64 (m, 3H), 7.95
(d, 1H). MS (ESI-): m/z = 407.15 [M-H]-.
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(43) 2-(4-(2-(2,4dichlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (dimethyl sulfoxide-d): δ = 3.09 (dt,
4H), 3.66 (t, 4H), 5.08 (s, 2H), 7.11 (d, 1H),
7.35 (m, 2H), 7.54 (d, 1H), 7.59 (d, 1H), 7.64
(t, 1H), 7.95 (d, 1H). MS (ESI-): m/z = 407.11
[M-H]-, 409.11 [M+2-H]-, 4011.15 [M+4-H]-.

(44) 2-(4-(2-(3,5dichlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (dimethyl sulfoxide-d): δ = 3.09 (dt,
4H), 3.66 (m, 4H), 5.01 (s, 2H), 7.10 (d, 2H),
7.17 (t, 1H), 7.34 (t, 1H), 7.54 (d, 1H), 7.64
(t, 1H), 7.95 (d, 1H). MS (ESI-): m/z =
407.09 [M-H]-, 409.10 [M+2-H]-, 411.11
[M+4-H]-.

(45) 3-(4-(2-(2chlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.22 (dt, 4H),
3.81 (dt, 4H), 4.82 (s, 2H), 6.93 (t, 1H), 7.02
(d, 1H), 7.12 (d, 1H), 7.20 (d, 1H), 7.36 (d,
2H), 7.61 (s, 2H). MS (ESI-): m/z = 373.15
[M-H]-, 375.16 [M+2-H]-.
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(46) 3-(4-(2-(2fluorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.21 (m, 4H),
3.79 (m, 4H), 4.81 (s, 2H), 6.94 (m, 1H), 7.06
(m, 3H), 7.12 (d, 1H), 7.34 (t, 1H), 7.62 (s,
2H). MS (ESI-): m/z = 357.18 [M-H]-.

(47) 3-(4-(2-(2(trifluoromethyl)phenoxy)acetyl)piperazin1-yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.20 (t, 4H), 3.82
(dt, 4H), 4.85 (s, 2H), 7.05 (t, 1H), 7.14 (t, 2H),
7.36 (t, 1H), 7.50 (t, 1H), 7.61 (m, 3H). MS
(ESI-): m/z = 407.17 [M-H]-.

(48) 3-(4-(2-(3chlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.24 (q, 4H),
3.79 (dt, 4H), 4.73 (s, 2H), 6.86 (d, 1H), 6.97
(d, 2H), 7.20 (d, 2H), 7.37 (t, 1H), 7.64 (m,
2H). MS (ESI-): m/z = 373.15 [M-H]-,
375.16 [M+2-H]-.
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(49) 3-(4-(2-(3fluorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.24 (q, 4H),
3.79 (dt, 4H), 4.73 (s, 2H), 6.72 (dd, 3H),
7.19 (dd, 2H), 7.37 (t, 1H), 7.64 (m, 2H). MS
(ESI-): m/z = 357.19 [M-H]-.

(50) 3-(4-(2-(3(trifluoromethyl)phenoxy)acetyl)piperazin
-1-yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.25 (q, 4H),
3.80 (dt, 4H), 4.78 (s, 2H), 7.16 (m, 3H),
7.27 (s, 1H), 7.40 (q, 2H), 7.65 (m, 2H). MS
(ESI-): m/z = 407.18 [M-H]-.

(51) 3-(4-(2-(4chlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.23 (q, 4H),
3.79 (m, 4H), 4.72 (s, 2H), 6.89 (d, 2H),
7.17 (d, 1H), 7.24 (d, 2H), 7.37 (t, 1H), 7.64
(m, 2H). MS (ESI-): m/z = 373.16 [M-H]-,
375.17 [M+2-H]-.
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(52) 3-(4-(2-(4fluorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.19 (m, 4H),
3.75 (m, 4H), 4.70 (s, 2H), 6.91 (d, 2H), 6.97
(t, 2H), 7.11 (d, 1H), 7.33 (t, 1H), 7.60 (m,
2H). MS (ESI-): m/z = 357.21 [M-H]-.

(53) 3-(4-(2-(4(trifluoromethyl)phenoxy)acetyl)piperazi
n-1-yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.25 (m, 4H),
3.80 (dt, 4H), 4.79 (s, 2H), 7.03 (d, 2H),
7.18 (d, 1H), 7.37 (t, 1H), 7.56 (d, 2H), 7.65
(m, 2H). MS (ESI-): m/z = 407.19 [M-H]-.

(54) 3-(4-(2-(2,4dichlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.24 (dt, 4H),
3.81 (m, 4H), 4.81 (s, 2H), 6.97 (d, 1H), 7.17
(t, 2H), 7.38 (q, 2H), 7.63 (m, 2H). MS (ESI): m/z = 407.13 [M-H]-, 409.14 [M+2-H]-,
411.15 [M+4-H]-.
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(55) 3-(4-(2-(3,5dichlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.26 (q, 4H),
3.78 (dt, 4H), 4.72 (s, 2H), 6.87 (d, 2H), 7.00
(t, 1H), 7.19 (d, 1H), 7.38 (t, 1H), 7.65 (m,
2H). MS (ESI-): m/z = 407.12 [M-H]-,
409.14 [M+2-H]-, 411.16 [M+4-H]-.

(56) 4-(4-(2-(2chlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.36 (m, 4H),
3.18 (dt, 4H), 4.82 (s, 2H), 6.86 (d, 2H), 6.94
(t, 1H), 7.02 (d, 1H), 7.21 (d, 1H), 7.37 (d,
1H), 7.98 (d, 2H). MS (ESI-): m/z = 373.17
[M-H]-, 375.19 [M+2-H]-.

(57) 4-(4-(2-(2fluorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.37 (m, 4H),
3.80 (q, 4H), 4.80 (s, 2H), 6.88 (d, 2H), 6.96
(m, 1H), 7.08 (m, 3H), 7.98 (d, 2H) MS (ESI): m/z = 357.17 [M-H]-.
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(58) 4-(4-(2-(2(trifluoromethyl)phenoxy)acetyl)piperazin1-yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.28 (dt, 4H),
3.80 (dt, 4H), 4.84 (s, 2H), 6.85 (d, 2H), 7.06
(t, 1H), 7.13 (d, 1H), 7.50 (t, 1H), 7.59 (d, 1H),
7.98 (d, 2H). MS (ESI-): m/z = 407.19 [M-H]-.

(59) 4-(4-(2-(3chlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.32 (dt, 4H),
3.78 (dt, 4H), 4.72 (s, 2H), 6.86 (m, 3H),
6.95 (m, 1H), 6.99 (s, 1H), 7.20 (d, 1H),
7.99 (d, 2H). MS (ESI-): m/z = 373.22 [MH]-, 375.13 [M+2-H]-.

(60) 4-(4-(2-(3fluorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.36 (q, 4H),
3.77 (m, 4H), 4.73 (s, 2H), 6.66 (m, 2H),
6.74 (d, 1H), 6.86 (d, 2H), 7.21 (d, 1H), 7.98
(d, 2H). MS (ESI-): m/z = 357.20 [M-H]-.

131

(61) 4-(4-(2-(3(trifluoromethyl)phenoxy)acetyl)piperazi
n-1-yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.70 (m, 4H),
3.76 (m, 4H), 4.77 (s, 2H), 6.86 (d, 2H),
7.15 (m, 2H), 7.27 (s, 1H), 7.41 (t, 1H), 7.97
(d, 2H). MS (ESI-): m/z = 407.22 [M-H]-.

(62) 4-(4-(2-(4chlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.36 (q, 4H),
3.77 (m, 4H), 4.72 (s, 2H), 6.88 (t, 4H), 7.24
(d, 2H), 7.98 (d, 2H). MS (ESI-): m/z =
373.12 [M-H]-, 375.21 [M+2-H]-.

(63) 4-(4-(2-(4fluorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.36 (m, 4H),
3.78 (m, 4H), 4.70 (s, 2H), 6.88 (d, 2H), 6.91
(d, 2H), 6.96 (d, 2H), 7.99 (d, 2H). MS (ESI): m/z = 357.18 [M-H]-.
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(64) 4-(4-(2-(4(trifluoromethyl)phenoxy)acetyl)piperaz
in-1-yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.37 (d, 4H),
3.78 (m, 4H), 4.79 (s, 2H), 6.87 (d, 2H),
7.03 (d, 2H), 7.56 (d, 2H), 7.99 (d, 2H).
MS (ESI-): m/z = 407.19 [M-H]-.

(65) 4-(4-(2-(2,4dichlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.36 (m, 4H),
3.80 (m, 4H), 4.80 (d, 2H), 6.87 (d, 2H),
6.96 (d, 1H), 7.18 (dd, 1H), 7.38 (d, 1H),
7.99 (d, 2H). MS (ESI-): m/z = 407.11 [MH]-, 409.14 [M+2-H]-, 411.21 [M+4-H]-.

(66) 4-(4-(2-(3,5dichlorophenoxy)acetyl)piperazin-1yl)benzoic acid
1
H-NMR (chloroform-d): δ = 3.39 (m, 4H),
3.77 (dt, 4H), 4.71 (s, 2H), 6.86 (s, 2H),
6.89 (d, 2H), 7.00 (t, 1H), 7.99 (d, 2H). MS
(ESI-): m/z = 407.15 [M-H]-, 409.22 [M+2H]-, 411.34 [M+4-H]-.
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Appendix B: Structures of All 72 GRI Compounds Tested in Initial Screening
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Appendix B continued.
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Appendix B continued.
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Appendix B continued.
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Appendix C: FS-3 Assay Results for 72 GRI Compounds. GRI 792685 is marked with
an asterisk because the first values are for the initial screen and subsequent screening
revealed this compound was not a potent inhibitor of ATX.
GRI
Compound
392104
519441
96880
93694
181450
984880
903782
792685*
945497
699043
260591
383012
1009281
831230
889621
792704
116842
185220
171085
974920
251021
856642
792685*
98169
499941
775870
935577
983375
928106
587636
983872
150435
186730
394776
983174
935854
408953

%
Inhibition
65.47
59.65
54.08
48.01
46.41
46.41
43.44
42.80
40.83
38.04
36.68
36.18
35.07
34.70
32.80
32.54
30.32
25.62
25.53
21.69
20.57
19.83
19.81
18.56
17.47
16.91
15.61
15.37
14.98
14.23
13.38
13.38
13.26
12.13
11.03
10.69
10.53

%
Error
3.18
1.74
0.22
4.36
2.65
2.44
4.31
4.90
3.92
0.89
0.94
2.75
0.55
1.54
1.11
2.05
0.98
0.41
1.16
0.72
3.26
0.45
8.91
2.54
4.15
4.36
0.69
1.60
1.36
2.20
3.06
2.90
2.90
3.03
1.28
1.81
3.90

GRI
Compound
924286
916417
750362
157313
903376
150773
926129
1002828
924729
1003901
990485
187772
559033
952589
186298
397344
782211
860725
776990
887232
916432
527238
402692
775975
916439
93185
928613
931195
929551
784713
506731
394710
682652
929716
181723
412751
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%
Inhibition
10.52
9.17
9.16
9.03
8.67
8.43
7.92
7.68
7.68
6.68
6.54
6.06
6.06
5.82
5.70
4.83
4.63
4.09
3.59
2.55
2.48
1.44
0.32
-0.74
-0.74
-0.99
-1.36
-1.86
-2.35
-2.48
-2.55
-3.35
-4.83
-8.29
-28.39
-53.34

%
Error
1.45
4.61
2.51
3.34
2.07
7.45
3.21
2.49
1.60
2.66
3.05
2.33
2.12
1.44
1.19
2.10
2.10
0.34
1.16
2.08
2.96
3.70
3.83
1.34
3.99
2.42
2.75
3.94
0.03
1.19
3.33
4.63
3.92
3.47
6.84
0.56

Appendix D: NPP6 and NPP7 Assay Results for GRI 392104 Analogs with Improved
Potency
Analog
GRI 392104
Ragle 11
Ragle 21
Ragle 22
Ragle 29
Ragle 32
Ragle 33
Ragle 42
Ragle 44
Ragle 48
Ragle 50
Ragle 51
Ragle 54

NPP6 % Response
92.2 ± 3.6
93.4 ± 0.9
89.8 ± 2.6
89.8 ± 1.2
94.0 ± 1.0
92.2 ± 2.7
95.8 ± 6.3
97.6 ± 4.5
91.0 ± 3.0
96.4 ± 3.1
89.2 ± 2.9
93.4 ± 4.2
95.2 ± 2.8

Appendix E: Analog 22 Potentiation of LPA effect on LPA2
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NPP7 % Response
86.3 ± 2.6
99.0 ± 3.7
89.5 ± 6.6
102.0 ± 9.4
114.1 ± 14.5
103.3 ± 9.0
93.1 ± 4.1
90.5 ± 3.1
90.2 ± 8.7
84.3 ± 3.6
87.3 ± 5.8
89.2 ± 7.3
103.3 ± 5.3

Appendix F: Spectral Information for Analogs 67 through 77.
(67) 2-(3,5-dichlorophenoxy)-1-(4-(3(trifluoromethyl)phenyl)piperazin-1yl)ethanone
1
H-NMR (chloroform-d): δ = 7.38 (t, 1H),
7.11 (m, 3H), 7.00 (t, 1H), 6.86 (d, 2H),
4.71 (s, 2H), 3.76 (dt, 4H), 3.23 (q, 4H). MS
(ESI+): m/z = 433.14 [M+H]+, 435.11
[M+2]+, 437.10 [M+4]+.

(68) 1-(4-(3-chlorophenyl)piperazin-1-yl)2-(3,5-dichlorophenoxy)ethanone
1
H-NMR (chloroform-d): δ = 7.19 (t, 1H),
7.00 (t, 1H), 6.90 (t, 1H), 6.84 (m, 4H), 4.70
(s, 1H), 3.74 (dt, 4H), 3.19 (q, 4H). MS
(ESI+): m/z = 399.15 [M+H]+, 401.01
[M+2]+, 405.12 [M+4]+, 403.12 [M+6]+,
407.14 [M+8]+.

(69) 2-(3,5-dichlorophenoxy)-1-(4-(3hydroxyphenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 7.12 (t, 1H),
7.00 (t, 1H), 6.85 (d, 2H), 6.45 (m, 3H),
4.70 (s, 2H), 3.73 (dt, 4H), 3.17 (q, 4H). MS
(ESI-): m/z = 379.25 [M-H]-, 381.27 [M+2], 383.26 [M+4]-.
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(70) 2-(3,5-dichlorophenoxy)-1-(4-(3methoxyphenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 7.19 (t, 1H),
6.99 (s, 1H), 6.85 (s, 1H), 6.54 (d, 1H), 6.46
(d, 2H), 4.70 (s, 2H), 3.78 (s, 3H), 3.74 (dt,
4H), 3.18 (q, 4H). MS (ESI+): m/z = 395.25
[M+H]+, 397.33 [M+2]+, 399.33 [M+4]+.

(71) 2-(3,5-dichlorophenoxy)-1-(4phenylpiperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 7.29 (t, 2H),
6.99 (t, 1H), 6.95 (d, 2H), 6.86 (d, 2H), 4.70
(s, 2H), 3.75 (dt, 4H), 3.18 (q, 4H). MS
(ESI+): m/z = 365.25 [M+H]+, 367.25
[M+2]+, 369.25 [M+4]+.

(GRI 182135) 4-(4-chloro-2methylphenoxy)-1-(4-(3-chloro-4hydroxy-5methoxybenzoyl)piperazin-1yl)butan-1-one
1
H-NMR (chloroform-d): δ = 7.09 (s,
1H), 7.06 (d, 1H), 7.00 (d, 1H), 6.90
(d, 1H), 6.70 (d, 1H), 4.00 (t, 2H),
3.92 (s, 3H), 3.60 (bd, 8H), 2.56 (t,
2H), 2.17 (s, 3H), 2.17 (m, 2H). MS
(ESI-): m/z = 479.08 [M-H]-, 481.08
[M+2-H]-, 483.05 [M+4-H]-.
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(72) (3-chloro-4-hydroxy-5methoxyphenyl)(piperazin-1-yl)methanone
1
H-NMR (d6-DMSO): δ = 6.95 (d, 2H), 3.85
(s, 3H), 3.42 (t, 4H), 2.69 (t, 4H). MS (ESI+):
m/z = 271.30 [M+H]+, 273.26 [M+2]+.

(73) 2-(4-chloro-2-methylphenoxy)-1-(4(3-chloro-4-hydroxy-5methoxybenzoyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 7.12 (d, 1H),
7.08 (d, 1H), 6.99 (d, 1H), 6.90 (d, 1H),
6.77 (d, 1H), 4.71 (s, 1H), 3.92 (s, 3H),
3.61 (bd, 8H), 2.02 (s, 3H). MS (ESI-): m/z
= 451.00 [M-H]-, 453.00 [M+2-H]-, 455.00
[M+4-H]-.

(74) 1-(4-(3-chloro-4-hydroxy-5methoxybenzoyl)piperazin-1-yl)-2-(3,5dichlorophenoxy)ethanone
1
H-NMR (chloroform-d): δ = 7.01 (m, 2H),
6.91 (d, 1H), 6.84 (d, 2H), 4.69 (s, 2H),
3.92 (s, 3H), 3.62 (bd, 8H). MS (ESI-): m/z
= 471.00 [M-H]-, 473.00 [M+2-H]-, 475.00
[M+4-H]-, 477.00 [M+6-H]-.
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(75) 2-(4-chloro-2-methylphenoxy)-1-(4(3-nitrophenyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 7.69 (m, 2H),
7.40 (t, 1H), 7.12 (m, 3H), 6.78 (d, 1H),
4.73 (s, 2H), 3.79 (q, 4H), 3.26 (q, 4H). MS
(ESI+): m/z = 390.33 [M+H]+, 392.33
[M+2]+.

(76) (4-nitrophenyl)(piperazin-1yl)methanone
1
H-NMR (chloroform-d): δ = 8.27 (d, 2H),
7.56 (d, 2H), 3.54 (dt, 4H), 2.68 (dd, 4H). MS
(ESI+): m/z = 236.45 [M+H]+.

(77) 2-(3,5-dichlorophenoxy)-1-(4-(4nitrobenzoyl)piperazin-1-yl)ethanone
1
H-NMR (chloroform-d): δ = 8.30 (d, 2H),
7.57 (d, 2H), 7.01 (t, 1H), 6.84 (s, 2H),
4.69 (s, 2H), 3.61 (bt, 8H). MS (ESI+):
m/z = 437.08 [M+H]+, 439.17 [M+2]+,
437.08 [M+4]+.
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Appendix G: NPP6 and NPP7 Assay Results for GRI 182135, 73, and 74
Analog
GRI 182135
Ragle 73
Ragle 75

NPP6 % Response
99.4 ± 4.9
99.4 ± 7.8
94.8 ± 3.0
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NPP7 % Response
99.2 ± 1.3
99.2 ± 5.0
114.5 ± 5.5

Appendix H: FS-3 IC50 Graphs for Analogs 73 and 74

Structure of Ragle 73
First IC50 Graph (Synergy 2 Plate Reader)

Second IC50 Graph (Synergy 2 Plate
Reader)

Third IC50 Graph (FlexStation Reader)

Structure of Ragle 74
First IC50 Graph (Synergy 2 Plate Reader)

Second IC50 Graph (Synergy 2 Plate
Reader)

Third IC50 Graph (FlexStation Reader)
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